

NOVEMBER 15, 2017 NEW YORK CITY, NY



Early stage investors, fundraising CEOs, scientist-entrepreneurs, strategic partners, and service providers now have an opportunity to Make a Compelling Connection


ONSITE GUIDE











CONTENT



R	E	S	
NY	G 2	01	7

	Welcome to RESI2	K
•	RESI Agenda 3	James III
•	RESI Innovation Challenge 5	YY
•	Exhibiting Companies 13	
•	Track 1: Therapeutics Investor Panels	- 19
•	Track 2: Device, Diagnostic, & HCIT Investor Panels	- 28
•	Track 3: Entrepreneur Workshops	- 35
•	Track 4: Asia-North America Workshop & Panels	- 37
•	Track 5: Partnering Forum	- 41
•	Sponsors & Media Partners	- 42

WELCOME TO RESI







On behalf of Life Science Nation (LSN) and our title sponsors Johnson & Johnson Innovation JLABS, WuXi AppTec, and McDermott Will & Emery, I would like to thank you for joining us at the first Redefining Early Stage Investments event to be held in New York City. LSN has been watching New York come together as a biotech hub, with new bio-incubators, infrastructure and development support emerging. RESI will turn the focus to the one missing ingredient for early stage life sciences in New York: capital. With hundreds of one-on-one investor meetings taking place today, RESI aims to bring New York startups across those 'last three feet' to secure financing rounds and partnerships.

We are delighted that McDermott, Will & Emery have joined WuXi AppTec and Johnson & Johnson Innovation JLABS as a RESI Title Sponsor. These companies all have deep expertise in the life science space, and a demonstrable commitment to helping early stage companies move their products forward. We're proud that RESI has become part of their global ecosystems.

In the Exhibit Hall today, we're excited to present the RESI Innovation Challenge. Out of over a hundred applicants, LSN's scientific review team selected 36 companies to participate as finalists. All the competing companies can be found in RESI's exhibit area, showcasing their technologies on poster displays. Inside your RESI badge you'll find five tokens of RESI Cash you can use to "invest" in the most promising of these technologies. The winning companies that attract the greatest amount of investment will be announced at the cocktail reception tonight.

In RESI Partnering, hundreds of senior executives from investment and strategic firms will come face to face with early stage entrepreneurs. With so many participants on both sides of the table, finding the right fit is more important than ever. By using the RESI Partnering platform to filter fellow attendees, you can book up to 16 meetings based on fit and begin dialogues with partners who align directly with your focus areas. With that match as a basis, RESI is a venue for compelling conversations between startups and investors in the life science space.

LSN would like to extend our thanks to the speakers participating on the RESI Investor Panels. RESI NYC includes a new panel dedicated to the city, called Why NYC? Why Now? The event also features panels on cutting edge areas of discovery such as Early Stage Therapeutics, Collaborative Virtual Pharma, and Healthcare IT, as well as emerging investor categories like Family Offices and Payer & Provider Venture Funds. RESI NYC also features the Asia-North America Workshops & Panels Track for entrepreneurs that are interested in finding a cross-border investor or strategic partner. RESI's panels and workshops are packed with experienced investors and strategic partners who will share their expertise on the current investment trends in their field.

We hope you have a productive day packed with meetings, new connections and up to date investment knowhow. We'll look forward to seeing you again during JPM week, at RESI San Francisco on January 9th, 2018!



Dennis FordFounder & CEO, Life Science Nation
Creator of RESI Conference Series





RESI AGENDA





	MERCK INVENTING FOR LIFE Track 1: Biotech Investor Panels	MEDMARC. Track 2: Device, Diagnostic, & HCIT Investor Panels	McDermott Will&Emery Track 3: Entrepreneur Workshops	Johnson-Johnson Innovation – JLABS – Track 5: Partnering Forum	
7:00	:00 - 8:00 AM: Registration & Breakfast				
8 - 8:50 AM	PANEL AND WORKSHOP SESSIONS START AT 9 AM				
9:00 - 9:50 AM	BIG PHARMA Pipeline Strategy for Preclinical and Early Clinical Assets	PAYER & PROVIDER VENTURE FUNDS The Technologies That Hospital Systems & Health Plans Are Seeking	LIFE SCIENCE NATION Connecting Products, Services & Capital FUNDRAISING BOOT CAMP	MORNING	
10:00 - 10:50 AM	WHY NYC? WHY NOW? New York City Is Gaining Momentum As a Biotech Hub	COLLABORATIVE VIRTUAL PHARMA New Development Models to Fight Diseases with No Treatment or Cure	VENTURE VALUATION GLOBAL SALVATION SERVICES DEAL & PRODUCT VALUATIONS	EARLY STAGE Partnering Forum	
11:00 - 11:50 AM	ANGEL INVESTORS Explaining the Process of Engagement	HEALTHCARE IT INVESTORS Leveraging Software to Lower Costs and Improve the Quality of Care	McDermott Will & Emery NEGOTIATING TERM SHEETS		
12:0	0 - 1:00 PM: Lunch E	Break			
		_			
	MERCK INVENTING FOR LIFE	ONTARIO	多 · · · · · · · · · · · · · · · · · · ·	Johnson Johnson innovation – JLABS –	
		ONTARIO CANADA Track 2: Device, Diagnostic, & HCIT Investor Panels	大學		
1:00 - 1:50 PM	Track 1: Biotech	Track 2: Device, Diagnostic,	Track 4: Asia-North America	Track 5: Partnering	
- 1:50	Track 1: Biotech Investor Panels EARLY STAGE THERAPEUTICS INVESTORS Investing Early in	Track 2: Device, Diagnostic, & HCIT Investor Panels MEDICAL DEVICE INVESTORS Investing in	Track 4: Asia-North America Workshop & Panels ASIA INVESTORS LANDSCAPE China Leads Charge to	Track 5: Partnering Forum AFTERNOON EARLY STAGE	
1:50 PM 2:00 - 2:50	Track 1: Biotech Investor Panels EARLY STAGE THERAPEUTICS INVESTORS Investing Early in Novel Therapeutics FAMILY OFFICES How Do Family Offices View	Track 2: Device, Diagnostic, & HCIT Investor Panels MEDICAL DEVICE INVESTORS Investing in Novel Engineering Due to the popularity of the family office panel, there's no panel scheduled	Track 4: Asia-North America Workshop & Panels ASIA INVESTORS LANDSCAPE China Leads Charge to North America ASIA MEDTECH INVESTORS Understanding Asian Medtech Market:	Track 5: Partnering Forum AFTERNOON	
1:50 PM 2:00 - 2:50 PM 3:00 - 3:50 PM 4:00 - 4:50 PM	Track 1: Biotech Investor Panels EARLY STAGE THERAPEUTICS INVESTORS Investing Early in Novel Therapeutics FAMILY OFFICES How Do Family Offices View Seed & Series A Rounds? CORPORATE VENTURE CAPITAL The Corporate Landscape Morphed	Track 2: Device, Diagnostic, & HCIT Investor Panels MEDICAL DEVICE INVESTORS Investing in Novel Engineering Due to the popularity of the family office panel, there's no panel scheduled to run during this time slot TALES FROM THE ROAD Successful Biotech & Medtech CEOs Share Their Story DIAGNOSTICS INVESTORS New Generation of Technologies Enabling Personalized Medicine	Track 4: Asia-North America Workshop & Panels ASIA INVESTORS LANDSCAPE China Leads Charge to North America ASIA MEDTECH INVESTORS Understanding Asian Medtech Market: Key Differences & Current Opportunities ASIA THERAPEUTICS INVESTORS Exploring Asian Therapeutic Industry:	Track 5: Partnering Forum AFTERNOON EARLY STAGE PARTNERING	

CELEBRATING FIVE YEARS OF GREAT IDEAS WITH YOU



It's been five years since we first turned on the lights at our flagship Johnson & Johnson Innovation, JLABS in San Diego.

Our Vision was to energize the life science innovation ecosystem by making it easier for entrepreneurs to translate their great ideas into transformative healthcare products.

Wow, has that vision taken off. Today we have not just one incubator, but a vibrant network of eight locations throughout North America-where over 170 resident life science companies are advancing their ideas.

We are proud to play a role in supporting the success of so many entrepreneurs devoted to improving the health of patients across the globe.

Imagine what we can do together

Johnson Johnson innovation

www.jlabs.jnjinnovation.com > @jnjinnovation



RESI INNOVATION CHALLENGE







We welcome you to participate in the RESI Innovation Challenge!





The RESI Innovation Challenge is a virtual investment contest, and the investor is you!

As you explore the exhibit hall, you will encounter 36 RESI Innovators showcasing their technology via poster displays. Along with your RESI attendee badge, you will find five RESI Cash tokens that you can use to 'invest' in the most promising RESI Innovators. Take a look around this collection of cutting-edge life science technology, and leave your RESI Cash with the entrepreneurs that most inspire you. The invested capital will be tallied up and the top three winners will be awarded during the cocktail reception at the end of the day. Winners will be featured in the Life Science Nation (LSN) newsletter with readership of 20,000.

- First Prize: Complimentary tickets to 3 RESI Conference Series events of your choice (2 tickets per event)
- Second Prize: Complimentary tickets to 2 RESI Conference Series events of your choice (2 tickets per event)
- Third Prize: Complimentary tickets to 1 RESI Conference Series event of your choice (2 tickets)



RESI INNOVATION CHALLENGE



RESI Innovators				
CLOUD DX	AXONIS	GlucoSet	SEN-Jam	BioFilm Pharma
Easel 1	Easel 2	Easel 3	Easel 4	Easel 5
LOCATEMOTION	AMBLYOTECH	empros pharma	B10DETEGO	BrainStemBiometrics The Brain Eye Mandrating Compacting
Easel 6	Easel 7	Easel 8	Easel 9	Easel 10
AVANCEN MPROVING NATIENT CARE AT THE REDIRECT	<u>Laminate</u> Medical Technologies	Sisu Glotal Health	Novintum BIOSCIENCE	Fesarius Therapeutics
Easel 11	Easel 12	Easel 13	Easel 14	Easel 15
APTEEUS Easel 16	Preora Healthcare Easel 17	bioharmony Easel 18	NEURONASAL Easel 19	Meissa Vaccines Easel 20
Laser 10	Lasei 17	Lasei 10	Lasei 17	Lasei 20
* MagCath	Carelingel	Seven Genes 7-Generation To Live Topother	Pamdeca	SCITECH
Easel 21	Easel 22	Easel 23	Easel 24	Easel 25
VAX-IMMUNE	Endo Shape	MIRIMUS	SinSa	neuroste er
Easel 26	Easel 27	Easel 28	Easel 29	Easel 30
euclises	RENOVO	BBN Cardio	Optina	MicroQuin
Easel 31	Easel 32	Easel 33	Easel 34	Easel 35
♦?re nosis		ns to all the 36 RE utics, medical dev		

Easel 36







Cloud DX Inc. is a leading competitor in the highly regulated digital healthcare industry. We provide remote patient monitoring hardware, software and recurring revenue services in a frictionless, reimbursable transaction model, coupled with a sales strategy that is driving rapid adoption among global healthcare providers. Our Cloud DX Connected Health products were invented and developed in Toronto, Canada, and Team Cloud DX won the first-ever Bold Epic Innovator Award at the Qualcomm Tricorder XPRIZE. Cloud DX is based out of Waterloo region, Canada with US headquarters in Brooklyn, NY. To find out more, please visit www.clouddx.com



Spinal cord injury (SCI) or damage to spinal cord axons, Spinal Corticospinal Tract (CST), is a medical condition that causes permanent changes in strength, sensation and function. Drs. Zhigang He and Oswald Steward discovered a breakthrough RNA therapy that enables regeneration of the connections in the spinal cord (CST) after trauma. Research studies proved treatment with this therapy (in rats) induced regeneration and recovered function to 95% of normal. This research has received over \$5 million in federal, foundation and private funding and the Proof of Concept (PoC) has been validated in 10 scientific papers. We are seeking investment to evolve this RNA therapy and delivery system and link the animal PoC with clinical testing of the therapy in humans/patients.



GlucoSet develops a novel continuous glucose monitor for critically ill patients, which will reduce complications and hospital cost. This market is estimated at 1.4B USD in the US and EU. The solution is unique in that it is reliable and very easy to adopt in clinical practice. The patented technology is designed for large scale manufacturing from the beginning. The management team has decades of industry and scale-up experience, and a history of successful exits. The company currently needs 8M USD to achieve CE mark in 2020, and a further 9M USD to launch the product in the EU and get market access in the US.



Sen-Jam Pharmaceutical is reimaging health through innovation. Sen-Jam's Exulta™ asset, a fixed-dose novel combination therapy, provides opioid free pain relief with GI protection for extended use. Exulta™ can stabilize the innate immune system by modulating histamines, prostaglandins and regulating pro-inflammatory cytokines. Exulta™ can also attenuate glial cell activity. Exulta's platform can be used for multiple indications: reducing opioid induced hyperalgesia, tolerance and dependence for all chronic opioid users, reducing symptoms of opioid withdrawal, treatment of arthritis, reducing common cold symptoms, reducing alcohol hangover symptoms, and preventing symptoms associated with vaccine administration. Exulta™ has been shown in volunteers to reduce symptoms associated with the innate immune response by 60-90% in over 500 dosing events without adverse effects. http://www.sen-jam.com



Biofilm Pharma develops innovative products in targeted infectious diseases, that are not antibiotics but a new class of drugs. Our unique technology, which has no competitor worldwide, is based on very early detection of biofilm formation and is protected by 10 patent families granted and covering 23 countries. The Company is aiming at reinforcing the therapeutic arsenal against a major unsolved issue: Antibiotic resistance; and proposes to develop a new generation of antimicrobials, what will succeed to antibiotics. BioFilm Control currently looks for a A series € 8m to lead among druggable compound libraries our 1st promising drug candidate. This First product will constitute a solution against Diabetic Foot Ulcer Infections to enter in toxicological preclinical stage.



An IoT / AI HealthCare Startup with a goal to help locate, track and monitor in real-time and to predict outcomes in real-time. Locate Motion solution is especially designed to take care of loved ones who are prone to wandering or may need support from time to time. As of today we have an upgraded IoT solution that works with Locate Motion's Consumer Mobile App and Business (Telco Co-branded) Web App. We have a road map to develop an IoT / Big Data / Al solution to NOT ONLY help track, talk, locate and monitor in real-time BUT ALSO with capability to provide individualized care, diagnosis and predict various outcomes. Our primary target segment is Alzheimer / Dementia / Autism and secondary segment is Elderly / Kids. We are also exploring PoC (Proof of Concept) Trials for diverse use cases with Banks (Wellness & health), Insurance, FMCG's, Business campaigns, Track employees, etc.



Amblyotech is a digital therapy company focused on treatments for neurological conditions, the first of which is Amblyopia. This ocular disorder affects 3% of the global population. The company, with its' partner, Ubisoft, has developed the Amblyotab, a patented android based device which have been clinically proven to successfully treat this condition. Amblyotech is filing for regulatory approval internationally and expects to launch in 2018.



EMP16 – a new approach to fighting obesity. Empros Pharma has developed a revolutionary oral drug – EMP16. The main mechanism of action for EMP16 is to delay normal food digestion and absorption processes towards the end of the small intestine. EMP16 thereby support and increase the natural satiety response present in the gastrointestinal system to regulate food intake. An important distinction to other, often hormone based satiety regulating pharmaceuticals (that will act on one or a few of the hormone signalling pathways) is that EMP16 enhances the entire endogenous hormone response in a physiological way. Empros Pharma expects EMP16 to be a safer and more potent method to address the medical need of obese patients.







BioDetego is developing a personalized molecular pathology platform that accurately determines a person's risk of cancer relapse and need for chemotherapy. Existing cancer staging guidelines provide little to no individualized data to identify patients that will benefit from adjuvant chemotherapy following surgery, resulting in a substantial number of patients who are undertreated or overtreated chemotherapy. To address this unmet clinical need, BioDetego has developed an innovative two-tier test platform based on the discovery of novel "driver" metastasis biomarkers. Our novel commercial strategy provides physicians with a cost-effective diagnostic approach that is consistent with the existing oncology care pathway and reduces the burn rate associated with commercialization.



We believe that there is a much better way to administer critical but potentially dangerous drugs to our most vulnerable ICU patients; the old and the young, who today are being over-medicated because today we use antiquated, subjective, sedation monitoring methods. BrainStem Biometrics Nanogold technology enables clinicians to administer sedatives in an optimal manner which is proven to reduce length of stay and direct costs by 25% and to reduce mortality significantly for over 24 million intensive care patients each year in the US, a multi-billion dollar uncontested market alone. The BrainStem Nanogold sedation system is the first noninvasive, wearable, continuous, direct monitor of core brainstem activity providing immediate feedback of the drugs physiological affect. With 510(k) clearance, strong patents, we have validated the business, are building a customer base and have substantial interest from several OEM partners (US, China, Japan). We are now ready to grow rapidly and looking for a few additional select investors to help us in 12 months either take the company to a point of strategic deal or to a substantial follow on investment to build a sales force.



Avancen's goal is to provide a positive value analysis for its customers while maintaining a high ROI for its investors through the sale of its products and disposables. Avancen has multiple patented products, regulatory approval and revenue. It has successfully built an exclusive national distribution network of regional specialty distributors and is on contract with the largest GPO in the USA. Avancen's first product the MOD® (Medication On Demand) along with its enterprise level software MODTrac® complete a system for the delivery of oral pain medication in acute care hospitals. The system provides increase patient satisfaction, significant saving of nursing time, an evidence based pain protocol designed to reduce opioid use, both during the hospital stay and at discharge.



Laminate Medical Technologies is a biomedical start-up founded in 2012 to develop VasQ, a blood vessel support device for patients receiving dialysis. The need for VasQ was clear: most patients who undergo hemodialysis for kidney failure require arteriovenous fistula for vascular access, and physicians rely on a 50-year-old technique with high failure rates to create it. More than half of patients experience vein blockage, necessitating multiple surgical or endovascular procedures to keep the fistula functioning. This cycle is very traumatic for patients. To address this problem, Laminate developed VasQ, an external scaffold that allows proper blood flow during dialysis while reducing vein blockage and other complications. VasQ is CE Marked and used in hospitals in Europe and Israel. U.S. Food and Drug Administration (FDA) clinical trials begin in 2017.



Sisu Global Health is the medical device company for emerging markets. Hemafuse, Sisu's first portfolio product, is a surgical tool that salvages and recycles a patient's own blood from internal bleeding. Hemafuse is a completely mechanical alternative to donor blood for cases of internal bleeding and trauma. Sisu recently achieved regulatory approval in Ghana and Kenya for Hemafuse and is entering into a market launch phase. Sisu has raised \$1.8M in funding (\$630k non-dilutive) from investors like Steve Case (founder of AOL), Camden Partners and Keiretsu Capital. Non-dilutive funding includes grants from USAID and Gates Foundation. Sisu has won awards such as the GE-Backed First Mile Innovation Challenge and features including Economic Times, Business Insider, and TEDxMidAtlantic.



Novintum Bio is a biotech group based in Switzerland and the UK with a team of 13 innovators and 4 externalised chemistry FTEs developing novel, small molecule, cancer therapeutics called Mitochondrial Metabolism Modulators. Novintum's compounds inhibit mitochondrial protein synthesis to modulate the metabolic and quality control processes of mitochondria in specific cancer cell subtypes including Treatment Resistant Cells, the population of cells that survive current treatments and which cause relapse and metastases. Over 350 NCEs have been synthesised in 4 programmes, two of which are in candidate optimisation. Novintum has three platforms – NoviChem, NoviGenesis and NoviAssay. The initial application in cancer will be to delay relapse in e.g. pancreatic cancer. The company has received seed and series A funding of \$13m from the Rising Tide Foundation.



Fesarius Therapeutics seeks to develop and ultimately manufacture a superior engineered tissue scaffold based on patent pending technology invented by Dr. Jason Spector in the lab he runs at Weill Cornell. He is also a world renown plastic and reconstructive surgeon at Weill and his clinical experience informs his regenerative research efforts. We feel this fact is and will continue to be compelling in supporting the substance of what he has developed and what we are creating from it. My brother and I have spent a lot of time and money reducing the execution risk for prospective investors including fully funding all of the patent, licensing, lab space buildout and most recently hired a chief scientific officer. We are currently seeking a F&F round to fund what we currently estimate is around a 24 month research effort to get to large animal data, which we believe will then provide the basis of a valuation sufficient to raise for the capital needed for human trial, FDA submission and execution of a commercial sales strategy.





APTEEUS

Apteeus is a clinical stage biotech company that captures new attractive markets for existing drugs. Apteeus uses its smart discovery engine to identify new drug candidates ready for the clinic in a couple of months. Apteeus technology allows unbiased screening of proprietary Apteeus library of drug and metabolites on primary cells from patients. Apteeus appealing pipeline currently contains 2 drug candidates that are developed for treating Epidermolysis bullosa and Rhabdomyolysis. We are seeking 15M€ to ensure their development up to registration and licensing planned for 2021. Apteeus is a clinical stage biotech company that captures new attractive markets for existing drugs. Apteeus uses its smart discovery engine to identify new drug candidates ready for the clinic in a couple of months. Apteeus technology allows unbiased screening of proprietary Apteeus library of drug and metabolites on primary cells from patients. Apteeus appealing pipeline currently contains 2 drug candidates that are developed for treating Epidermolysis bullosa and Rhabdomyolysis. We are seeking 15M€ to ensure their development up to registration and licensing planned for 2021.

Preora Healthcare

Preora Healthcare is focused on developing technologies that advance early detection and effective treatment of cancer. We do this by identifying and measuring nanoscale structural changes within individual cells. Understanding cellular nano-structures enables cytologists, physicians and researchers increase their impact and influence in cancer diagnostics. Our core technologies fall into three distinct yet complementary areas: Automated Sample Preparation, PWS NanocytologyTM Fixed Cell Imaging, and PWS NanocytologyTM Live Cell Imaging. In the next 24 months, we will leverage these technologies to advance sample preparation in fine needle biopsy procedures and address the unmet clinical need in lung and colorectal cancer screening.

bïoharmony

Bioharmony Therapeutics is an early-stage biotechnology company developing next-gen antimicrobial therapies for lethal drug-resistant bacterial infections. We are exploiting millions of year of phage-bacteria evolution to develop lysins, enzymes produced by phages that rapidly kill bacteria and have a very low chance of developing resistance. Our lead product targets infections caused by Acinetobacter baumannii, a MDR-pathogen that poses the greatest threat to human health. Our pipeline targets infections caused by other Gram-negative bacteria such as E.coli and Klebsiella, for use in UTI, pneumonia and sepsis.



Concussions have no FDA approved treatment. (More than 2 million US concussions/year); approximately 20% result in persistent symptoms- disturbed concentration/sleep, headaches, etc. Neuronasal is developing intranasal (IN) n-acetylcysteine delivery which has shown reduction of post concussion symptoms in US soldier trial using very high oral doses required because of poor bioavailability. IN delivery circumvents this problem. This human trial and IN animal model tests suggest that IN delivery of the drug directly to the brain will be an effective/safe delivery route. Neuronasal LLC, the University of Michigan and the U.S. Army are proposing a IN N-acetylcysteine clinical trial to reduce post-concussive symptoms. NN has broad patent coverage for this type of drug delivered IN. Ready for Phase I.



Meissa Vaccines is applying novel synthetic biology techniques to create vaccines against major viral diseases that have proven refractory to traditional vaccinology: first RSV and then related respiratory viruses. Meissa's innovation is to genetically modify live viruses to be both attenuated and immunogenic. RSV is the leading cause of hospitalization of infants in the US. The technologies were licensed from Emory University, published in Nature Communications, and have the potential to be applied to multiple respiratory targets. Our seasoned biotech team knows vaccine development, and we have initiated CMC using angel round and SBIR funds. We think the RSV market size, market certainty, and elegant technologies make Meissa a unique opportunity that is unlike a typical vaccine project.



Stress Urinary Incontinence (SUI) is a significant problem for very many women. We estimate that up to 15 mill women in US & Europe suffers from SUI.We have developed and patented a single use medical device, that can greatly help women suffering SUI to manage and control their urine voiding and thereby their daily life. Our device is a sterile, soft silicone urethral catheter with an integrated valve. Clinical trials at the University Hospital of Copenhagen, Denmark have been finalized successfully. Doctors's conclusions are that our device is safe, efficient and user friendly. We now seek investment of up to USD 2 million, sufficient to get us Market Access, CE-mark and FDA 510K early 2019.



Care Angel offers the world's first voice AI, Virtual Nurse Assistant. Angel enables the most effective, efficient and scalable way to engage monitor and manage large, at-risk populations with complex and chronic conditions at the lowest cost, starting with a simple phone call. Care Angel gives care teams the ability to collect accurate patient data, consistently. At the same time, receiving regular updates on vitals and well-being to inform and manage real-time interventions. Care Angel's multi-modal engagement platform helps providers and payers to automatically close gaps in care. There is also the flexibility to extend the platforms capabilities to push specific and configurable notifications to family and friends, strengthening the communication, connection, and partnership with patients and their families. Our offering is proven to lower costs, and improve medical and financial outcomes, resulting in a strong ROI for our clients.







Sevengenes is an early stage biopharmaceutical company focused on developing drugs by significantly enhancing the solubility, bioavailability, and efficacy of new molecules and generic drug molecules while minimizing systemic toxicity utilizing a novel excipient, 7GEN (Patent Pending) hitherto unknown to the pharma industry. The first drug product, SG101, is the combination of 7GEN, and a plant-derived molecule; this well-studied molecule never made into a drug because of its solubility and toxicity issues but 7GEN can solve those issues based on our preclinical results. 7GEN can improve solubility, bioavailability, and efficacy of many generic drug molecules, including paclitaxel. SG102 is the combination of 7GEN and Paclitaxel and based on our pharmacokinetic data, 505(b)(2) route will be pursued for the drug approval process for breast cancer and pancreatic cancer.



Pamdeca LLC is a development stage immuno-oncology start-up. We have discovered a unique way to activate a natural cancer-killing program in macrophages, and are developing a new class of 2nd generation immuno-oncology drugs based on this mechanism. Our drug candidate passed Proof-of-Principle testing in three ovarian cancer animal models, demonstrating a strong anti-cancer effect, converting tumor-associated macrophages from an M2-like (tumor-promoting) to an M1-like (tumor-destroying) phenotype. Based on its mode of action, we plan to develop our NCE as a companion drug to immune checkpoint inhibitors, anticancer vaccines, and CAR-T therapies. Pamdeca is a Northwestern University spin-out with a strong IP position and an experienced founding team focused on product commercialization. We are seeking seed funding of ~\$900K.



SciTech Development is a clinical stage, biopharmaceutical company led by an NCI-affiliated, highly experienced team of seasoned drug and commercial development professionals. Our clinical lead compound is an accelerated, short-development track, drug product (nano-fenretinide or ST-001) delivered in a novel, intravenous system for the management of an orphan T-cell lymphoma and then for a cadre of other tumor-types of unmet need. ST-001 has overcome drug delivery hurdles that have stalled use of this famous anticancer agent (fenretinide) that previously demonstrated significant oncolytic activity. An IND application was filed and negotiated with the FDA yielding a clear path to approval; Orphan Drug and Fast Track applications were also submitted; and a test batch of ST-001 was manufactured to IND negotiated standards.



Vax-Immune's LabReady answers a large unmet need - the prevention of false negative/positive results - by the optimal collection and transport of microbiology samples. This is complemented by inclusion of diagnostics in the device. LabReady is a proprietary, portable, disposable, hand-held device. It collects, processes, grows, transports and diagnoses infection as samples move from patient to laboratory. LabReady strips out the loss of sample quality and time from collection to testing. There is no product like it on the market. LabReady makes diagnosing infection faster, easier, cheaper, and more accurate, by moving the laboratory to the patient. It re-imagines the lab where everything happens before the sample arrives.



EndoShape is venture-backed company in Boulder, Colorado that has developed a unique polymer-based implant to occlude blood flow in peripheral vessels involving hemorrhage, vessel trauma, tumor treatment, or vessel abnormalities. The EndoShape design provides significant clinical advantages - including the ability to occlude with only one implant, be visible under fluoroscopy, and yet be followed with CT/MRI imaging. The polymer and device design provide the physician the ability to precisely place the implant for optimal vessel occlusion. In addition to unique proximal and distal design, the polymer science employed results in radiopacity during the procedure and no imaging artifact in follow-up. The EndoShape design has been proven in preclinical environments including acute performance studies and chronic implant studies. EndoShape is led by a staff experienced in neurovascular occlusion technology, guidewires, catheters, and in medical polymer formulations. The EndoShape Scientific Advisory Board is composed of vascular surgeons and interventional radiologists.



Mirimus is engaged in the design, development and pioneering of new genome editing technologies to develop animal models that are crucial for the preclinical evaluation of new therapeutics. We are a high-tech business unlike any other with expertise in RNAi technologies critical for development of animal models that can pave the way we develop drugs, by pin-pointing potential toxicities and guiding the development of safer, more effective therapeutics. We are revolutionizing the creation of animal models by synergzing RNAi and CRISPR/Cas9 technologies for development of mice, rats and higher organisms.



SinSa Labs bioengineers Superdrugs to fight the world's Superbugs. Our platform is an entirely new class of antibiotics, and is based on a decade of exclusively licensed, cutting-edge research that has generated more than 25 publications in prestigious journals, numerous patents, and a rich pipeline of 150 membrane-active new molecular entities. B2088, SinSa's lead compound, is uniquely effective against drug-resistant Gram-negative bacteria, an area of high unmet medical need, and will be in clinical trials for chronic cUTI in Spina Bifida Myelomeningocele patients, an orphan indication, in 2018 with a view to approval in 2021.







Neurosteer is a pioneer of a miniature, wearable and affordable brain sensing platform for a wide range of medical, wellness and lifestyle applications. A sticker-size, sticker-thin sensor offers medical grade accuracy using three EEG electrodes on the forehead and proprietary cloud-based software, providing unique biomarkers and alerts on cognitive load, emotional states, sleep and pain, abnormal (epileptic) activity, disorders of consciousness and level of anesthesia. Neurosteer's initial focus is the Healthcare industry. Specifically, providing affordable screening and a companion brain monitor for clinical trials (pre-FDA). Post-FDA, provide post-trauma epileptic activity alerts in ICUs and real-time anesthesia level assessment. Next, Neurosteer will disrupt Digital Health by promoting wellness applications. Ultimately, provide a platform to developers, using the "powered by Neurosteer" strategy.



Euclises Pharmaceuticals, Inc., is focused on development of a novel class of anti-cancer drugs. In the immuno-oncology (IO) setting, Euclises' lead candidate (ECP-1014) turns cold tumors "hot" via COX-2 inhibition and suppression of PGE-2 levels. In combination with various checkpoint inhibitors (CI), ECP-1014 potently blocks PGE-2 inhibition of CI-induced immune response to animal tumors. In animal models that are otherwise non-responsive to CI therapy, these IO combinations result in complete tumor elimination. PGE-2 also directly drives cancer cell proliferation in a number of human tumors, and ECP-1014 has been shown to directly inhibit growth of human tumor animal xenografts as a single agent and in combination with other targeted therapies. ECP-1014 has competed pre-clinical testing, and Euclises is preparing to take it into a biomarker-driven Phase 1/2 study in cancer patients.



RenovoRx has developed a novel therapy for pancreatic cancer with strong early efficacy results. Data on a recently published safety study demonstrates a patient pathway demonstrating 28-month survival vs. historical control survival of 14-15 months in this patient group. The technology is currently being used in a few centers across the country in a post-market registry with over 200 revenue procedures performed to date with existing reimbursement coding. RenovoRx has recently begun the next phase of the company: launching a randomized study to further validate these findings which then positions the company to fully engage a multi-billion dollar worldwide market.



BBN Cardio Therapeutics is a preclinical pharmaceutical company that has developed a drug to treat the plaques that contribute to atherosclerosis, a major factor in heart attacks and strokes, which are leading causes of death in the US and worldwide. Pa/HDa-216 is intended to be an adjunct to statin therapy and employs a novel mechanism of action that directly targets atherosclerotic plaque. Our research has produced several successful human and animal studies. The Cleveland Clinic study that showed a substantial reduction of atherosclerotic plaque in ApoE-/- mice. This study became the foundation of our US Patent 9,808,437 (11/07/17) that protects our composition and method through October 2035. International patent applications have been filed in 6 other countries and the EU.



Optina Diagnostics specializes in developing state-of-the-art diagnostics for early, non-invasive detection of disease via the eye, with a primary focus on the diagnosis of Alzheimer's disease (AD). The company combines its patented machine learning method to hyper spectral fundus imaging (licensed from Caltech) to make detection of the disease possible before symptoms appear and irreversible damage occurs. Our pharma services identify large cohort of asymptomatic and mild cognitively impaired subjects for drug trials. Our clinical diagnostic will shorten the time (2.7 years) and cost of an accurate diagnosis. Our screening services will allow access to therapy-modifying disease.



MicroQuin is a US and UK based biotechnology company with first-in-class lead compounds that use two technologies to kill breast cancers. Our first technology is a cell penetrating peptide which can selectively bind to cancerous cells, ignoring healthy cells, and force internalization of any therapeutic payload. Our second technology is a protein-based drug which selectively induces cell death in cancerous cells, having no effect in healthy ones. MicroQuin's products are market disruptors that initially aim to reimagine the \$2.1 billion triple negative breast cancer treatment market. Through academic collaborations, in-house expertise, including the former head of oncology at AstraZeneca, and advisors from Cancer Research UK, MicroQuin aims to expand its pipeline and bring lead compounds to clinical trials by 2021.




Prenosis delivers true precision medicine for acute care facilities by utilizing a powerful predictive analytics system that predicts the risk of infection related adverse events for individual patients in real time. The system combines real time data inputs from Electronic Medical Records (EMRs) with fundamentally relevant blood biomarker data measured either in a clinical lab or using a handheld point of care device. The first product, planned for early 2019 release, is a platform agnostic software system for use in Emergency Departments, in-patient populations, and ICUs. The second product, a combined handheld device with accompanying analytics, will be released by early 2021.




Global Platform. One Vision.



Small Molecule R&D and Manufacturing



Biologics R&D and Manufacturing



Cell Therapy and Gene Therapy



Medical Device Testing



Genomics and Molecular Diagnostics

>16,000

employees worldwide

>3,000

collaborators around the world

27

sites and offices worldwide

6,000,000

sq. ft. of lab and manufacturing space







Exhibiting Companies				
Johnson Johnson innovation – JLABS –	McDermott Will&Emery	MEDMARC. Treated Fairly	Pfizer	
Table 1	Table 2	Table 3	Table 4	
LIFE SCIENCE NATION Connecting Products, Services & Capital	Boston Innovation Capital Robert & Montest Providenting	ONTARIO	Extriode Product Strategy	
Table 5	Table 6	Table 7	Table 8	
TriNet Ambitions Realized	COTÉ orphan « QuinterMit dengary	多 明 康 德 WuXi AppTec	WuXi AppTec IND	
Table 9	Table 10	Table 11	Table 12	
WuXi Biologics Global Solution Provider	\$\tangle\$ LabNetwork		HIREtech™	
Table 13	Table 14	Table 15	Table 16	
MEDTECH CONFERENCE	VENTURE VALUATION SLOBAL VALUATION SERVICES	Foundation Venture Capital Group u.c A New Jersey Health Foundation Affiliane	pai	
Table 17	Table 18	Table 19	Table 20	
KINETA innovation from within™ Table 21				





Johnson Johnson innovation

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow – all in a no-strings-attached model. The JLABS network includes eight facilities, located in San Diego the Bay Area, Boston & Lowell, MA, Houston, Toronto including a new location, New York City, launching in 2018.

McDermott Will&Emery McDermott Will & Emery is a premier international law firm with a diversified business practice. Established in 1934 as a tax practice in Chicago, Illinois, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. McDermott has 80 years of serving a broad range of client interests. Our Life Sciences Industry Group is composed of 135 professionals, 60 with advanced science degrees and many others with government and industry experience, working across 19 offices around the world. With insights drawn from the only health practice ranked Tier 1 nationally by Chambers USA and our global reach, we deliver integrated business solutions to our clients, bringing the required experience from our leading tax, health, intellectual property, antitrust and regulatory practices to solve our client's challenges.



Created in 1979 by the healthcare technology industry, Medmarc's purpose is to be the superior provider of liability insurance and related risk management solutions and to support the development, testing and delivery of medical products that save lives and improve the quality of life. Through collaboration with our parent company, ProAssurance, and our clinical trial industry experts, we provide a single source of innovative healthcare liability insurance solutions to the life sciences companies we serve. From ideas and prototypes to the reality of commercialization and success – We can Meet Your Changing Needs. Call me to discuss the cost of insurance coverage, what coverages are needed and when for your business plan. George Ayd (703)652-1309



At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.



Life Science Nation (LSN) accelerates fundraising using its matching platform to create highly compatible relationships between early stage scientists/ entrepreneurs and emerging technology investors. LSN researches and curates market intelligence on two industry sectors: The first is emerging biotech and medtech companies, which by their ephemeral nature are challenging to find and track. Second, LSN tracks ten categories of early stage life science investors and identifies who is filling the void left by venture capital. LSN owns and operates the Redefining Early Stage Investments (RESI) conference series, which brings together global early stage biotech and medtech companies with early stage investors.



Boston Innovation Capital (BIC) is an advisory firm that was spun out of Life Science Nation (LSN) in 2014 to address an unmet need among early stage scientist-entrepreneurs for tactical, hands-on assistance in packaging management teams and technologies, and executing fundraising campaigns. Traditionally, there are two alternative paths that can be used to address early-stage fundraising needs for life science companies; hire an internal business development executive at a cost of \$150k -\$250K annually, or find a small-tier investment bank that would be willing to undertake their financing. Boston Innovation Capital was created as a new, more effective and flexible solution to provide this global outreach service, and help new life science technologies take the next step towards the market by augmenting management teams' outbound campaign initiatives.



The Export Services Branch assists Ontario companies in accessing international markets by establishing partnerships and distribution channels and by providing assistance to foreign parties interested in sourcing Ontario products technology and services. If you are an international buyer looking to source goods or services from Ontario, visit: SourceFromOntario.com







At Triode, we are an amazing team of strategists, designers and engineers specialized in creating breakthrough products and services. Our goal: Help you find your growth vector and capture value. We work with you closely to help define product strategy, with an emphasis on reducing the risks associated with innovating in sophisticated and often regulated patient-oriented environments.



TriNet provides small and midsize businesses with a full-service HR solution so they can free themselves from the complexities of HR and focus on their goals. As their trusted HR business partner, TriNet assumes many of the responsibilities of being an employer and helps these companies contain HR costs, minimize employer-related risks and relieve the administrative burden of HR. TriNet offers bundled HR products tailored by industry, and strategic HR services, resulting in a comprehensive and empowering solution.



Coté Orphan, a QuintilesIMS company, is a full-service regulatory group with a laser focus on Orphan Drugs. From lab to the market, we take your idea to the FDA and EMA for approval. Currently 25 professionals strong, half with PhD's, it was founded in 2012 by Timothy R. Coté, MD MPH, former Director of the FDA's Office of Orphan Product Development (OOPD), and acquired by QuintilesIMS in 2017. CotéOrphan has an unparalleled understanding of the "unwritten" rules of orphan drug designation and product approval, and over 350 innovative biotechnology and pharmaceutical clients. We are passionate about bringing new drugs for rare diseases to the people who so desperately need them.



WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit http://www.wuxiapptec.com



As a key business within WuXi AppTec's diversified portfolio, the Laboratory Testing Division (LTD) is a unique testing powerhouse with operations in China and US. LTD's integrated services in drug development, medical device and clinical diagnostics span from preclinical development to clinical sample analysis. To better meet the need of integrated services, WuXi AppTec IND (WIND) is consolidated as a solution program for IND projects by integrating the service packages of analytical development, drug metabolism and pharmacokinetics, bioanalysis, toxicology, program management and regulatory affairs. With comprehensive service coverage and flexible collaboration models, LTD is well positioned to enable our customers to accelerate R&D processes and empower them to bring new, innovative medicines to patients in an efficient and cost-effective way.



WuXi Biologics is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit: http://www.wuxibiologics.com



LabNetwork, a WuXi AppTec company, is a global eCommerce platform connecting suppliers and buyers of research products. Backed by WuXi's expertise in R&D, sourcing, quality control, warehousing and logistics, LabNetwork brings novel and high-quality compounds from WuXi's global network of qualified providers to the chemistry and research communities worldwide. We enable scientists anywhere in the world to leverage the LabNetwork platform to conduct their research more efficiently and cost effectively. For researchers, LabNetwork provides sophisticated web and mobile tools that allow customers to use keyword/chemical structure/list search with intelligent ranking to get the best result. On a platform built for speed, ease of use, and big data, buyers can make informed decisions based upon cost, speed of delivery, and product quality.





OFTE PASSAGE

STA Pharmaceutical, a WuXi AppTec company is a trusted global partner for pharmaceutical development & manufacturing. End-to-end drug substance services including API development and manufacturing, chemical synthesis route selection, process development and optimization, scale-up process research and is capable of producing intermediates and APIs from kg to metric ton scale. Drug product services include developablity & formulation research, formulation development & optimization, phase I-III clinical supplies cGMP manufacturing with commercial drug product manufacturing capability coming online at the end of 2017. WuXi AppTec is an innovation-driven, leading global pharmaceutical, biopharmaceutical, and medical device outsourcing company with US and China operations helping customers shorten R&D timelines and lower R&D costs through cost-effective efficient solutions.

HIREtech"

HIREtech is a technology-focused Human Capital Management provider and Tax Incentive firm that helps companies with complex tax and HR workflows. Exclusive technology and business process outsourcing helps companies make important business and planning decisions, while saving time and money, and reducing risk. Services include the Research & Development Tax Credit, the Startup Tax Credit, Grants, and other technical tax incentive programs. Our experienced team of tax attorneys and PhDs ensure maximized tax credit capture with audit support, combined with award-winning customer service.



The MedTech Conference powered by AdvaMed is the leading gathering in North America of global medtech executives with regulatory, reimbursement, business development, legal, IP, marketing, quality, compliance, HR and other key responsibilities. More than 2,500 attendees will network, conduct business, gain access to capital and share insights in Philadelphia from September 24-26, 2018. The conference also features world-class plenary speakers, networking, and business development opportunities. Along with industry leaders, the international conference attracts business development professionals, investors, policy-makers, members of the media, legal experts, consultants, distributors, and other important stakeholders.



Venture Valuation specializes in independent assessments and valuations of companies in high-growth markets, such as biotechnology, life sciences and medical technology. Venture Valuation offers independent company valuations for fund raising as well as product valuations for licensing deals.



Foundation Venture Capital Group, an affiliate of New Jersey Health Foundation, invests in commercially viable new start-up companies developing health-related technology at major research organizations in New Jersey. FVCG portfolio companies currently include Actinobac Biomed: Affineti Biologics; Celvive, Durin Technologies; GeneAssess; MentiNova; NovoPedics; Snowdon Pharmaceuticals and Visikol. For more information visit: www.foundationventure.com.



PAI Health motivates people to become more physically active while enabling insurers and employers to monitor risk. PAI (Personal Activity Intelligence) measures all activity, allowing companies to identify high-risk individuals. Through the PAI system, users can improve their health with a personalized prescription for exercise, leading to cost savings for insurers. PAI is a heart-rate based metric that can reduce the risk of cardiovascular disease and other lifestyle diseases by up to 25%, as validated based on data from an extensive health study. PAI software is device agnostic and integrates with existing systems.



Kineta is a privately held emerging biotech company that was founded in 2008. Our mission is to develop novel immuno-therapies that transform patients' lives. Kineta has established a focused pipeline of life improving therapies that address critical unmet patient needs. We have leveraged our expertise in immunology to advance novel drug development programs in oncology, neuroscience and virology. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research. Kineta fills a void in the biopharmaceutical industry by efficiently advancing first in class immunotherapies from discovery to clinical proof of concept.



Fueling Your Mission

McDermott Will & Emery's Life Sciences Entrepreneurs Acceleration Program (LEAP) helps emerging companies avoid costly mistakes and chart their course for success. We provide strategic legal advice at crucial foundational stages of a company's lifecycle using a variety of flexible and deferred fee arrangements.

Learn more at www.mwe.com/leap/ or visit our table in the exhibition area!

www.mwe.com







McDermott Will & Emery conducts its practice through separate legal entities in each of the countries where it has offices. This communication may be considered attorney advertising, Previous results are not a guarantee of future outcome.



RESI

REDEFINING EARLY STAGE INVESTMENTS







RESI CONFERENCE SERIES



















TRACK 1: THERAPEUTICS INVESTOR PANELS





Track 1 **Moderator & Panelists** 9:00 - 9:50 AM • Joseph Simeone, Director, Enabling Technologies, BD&L, Merck Research Laboratories (M) BIG • Anders Linden, Sr. Manager Business Analytics & Transactions, Johnson & Johnson Innovation • Monica Cheng, BD & Licensing/Prescription Medicine - Cardiometabolic, Boehringer Ingelheim **PHARMA** • Shiv Krishnan, Sr. Director, Head, Partnering, External Sciences & Innovation, Global BioTherapeutics, Sanofi Pipeline Strategy for Preclinical • Sree Kant, Executive Director, Strategy, External R&D Innovation, Sanofi and Early Clinical Assets 10:00 - 10:50 AM • Carlo Yuvienco, Senior Project Manager, New York City Economic Development Corporation (M) WHY NYC? • Blake Stevens, General Manager-LaunchLabs, Alexandria Venture Investments • Eva Cramer, President, Downstate Biotech Incubator & BioBAT, NY Science & Technology Center WHY NOW? • Kate Merton, Site Head - JLABS @ NYC, Johnson & Johnson Innovation New York City Is Gaining • Mary Howard, Program Manager, ELabNYC Momentum As a Biotech Hub 11:00 - 11:50 AM • Yaniv Sneor, Founding Member, Mid Atlantic Bio Angels (M) **ANGEL** • Jennifer Seibert, Managing Director, Golden Seeds • Richard Dixon, Member, Houston Angel Network **INVESTORS** • Victoria Pettibone, Managing Director, Astia Angels Explaining the Process of • Wei Tao, Member, Sand Hill Angels Engagement 1:00 - 1:50 PM • **Ikechukwu Oji**, Business Development & Licensing, Bayer Healthcare (M) **EARLY STAGE** • Daniel O'Connell, Investment Manager, Arix Bioscience • Diyong Xu, Senior Associate, OrbiMed Advisors **THERAPEUTICS** • Jonathan Mandelbaum, Principal, Accelerator Corporation Investing Early in • Scott Weiner, Partner, Pappas Ventures **Novel Therapeutics** 2:00 - 2:50 PM • Ron Paliwoda, Founder & President, The Paliwoda Group (M) **FAMILY** • Chuck Stetson, CEO, Stetson Family Office • Kevin Schimelfenig, CEO & Managing Partner, McGeever OFFICES • Mark Groner, Vice President, Sopris Capital How Do Family Offices View • Sherry Grisewood, Chief Investment Officer, FoxHill Asset Management Seed & Series A Rounds? 3:00 - 3:50 PM • Elaine Jones, Vice President, Venture Capital, Pfizer Venture Investments (M) **CORPORATE** • Charles Kunsch, Director, AbbVie Ventures **VENTURE CAPITAL** • Claire Leurent, Bio Sector Investment Director, Samsung Ventures America • Eric Feinstein, Investment Director, Northwell Ventures Corporate Landscape Morphed: & New Opportunities Abound 4:00 - 4:50 PM • John Walter, CEO & President, The Alliance for Cancer Gene Therapy (M) • Andres Hurtado-Lorenzo, Director of Translational Research, Crohn's and Colitis Foundation **VENTURE** • Alyssa Reimer, Associate Director, Research Partnerships, The Michael J. Fox Foundation PHILANTHROPY • Kenneth LaMontagne, VP of Research, Leukemia & Lymphoma Society

• Michael Batten, Director, Strategic Partnerships, JDRF T1D Fund



Funding Innovation to

Improve Patient Care







ullet Joseph Simeone, Director, Enabling Technologies, BD&L, Merck Research Laboratories $\langle extbf{M}
angle$



Joe is currently a Director within the Enabling Technologies group of Merck Research Labs Business Development and Licensing department. His current focus is on the search and evaluation of technologies for drug delivery/formulations and all aspects of biologics discovery and development. Prior to the S&E role, Joe was responsible for transacting discovery focused business deals in support of several therapeutic areas. Joe joined Merck in 1993 as a chemist and over his seventeen year career in the laboratory he held several positions of increasing responsibility within the discovery and pre-clinical organizations. Joe received his Ph.D. in Organic Chemistry from Seton Hall University studying applications and mechanisms of palladium-catalyzed cross-coupling reactions.



• Anders Linden, Sr. Manager Business Analytics & Transactions, Johnson & Johnson Innovation

Anders is based in Cambridge, home to one of J&J's four Innovation Centers. The Innovation Centers are J&J Innovation's regional hubs, created to access cutting-edge science and technology in the region. At the Innovation Center, Anders is responsible for structuring and negotiating transformational deals with a multitude of diverse partners ranging from biotech companies, venture capital, startups to academic institutions with the aim to access early stage innovation across J&J's areas of interest – Pharmaceuticals, Consumer and Medical Devices. Prior to joining J&J Innovation Anders has held business development and transactional roles within J&J Supply Chain and the airline industry. Anders received his M.Sc. in Supply Chain Management from Linköping University Sweden and Technische Universität Darmstadt Germany.



• Monica Cheng, BD & Licensing/Prescription Medicine - Cardiometabolic, Boehringer Ingelheim

Monica Cheng is the Deputy Global Head of Business Development & Licensing (BD&L) for Cardiometabolic Diseases at Boehringer Ingelheim (BI). She joined BI's BD organization in 2008, her responsibilities include development and implementation of partnering strategy and support of all partnering activities related to the Cardiometabolic therapeutic area. She also led BI's BD&L for Infectious Disease until BI exited the space in 2013. Prior to joining BD, Monica was head of a research lab within BI's Cardiovascular Research organization. She received her PhD in Pharmacology from New York Medical College and her BS in Microbiology from University of Minnesota.



• Shiv Krishnan, Sr. Director, Head, Partnering, External Sciences & Innovation, Global BioTherapeutics, Sanofi

Shiv Krishnan leads Business Development and Licensing for Technology Platforms in Sanofi covering areas such as Biologics, Drug Discovery and Translational Sciences. Shiv obtained a BS in Zoology from American College, Madurai and went on to do a PhD in Protein Sciences at the University of Technology, Compiegne, France. After working in France for nearly 2 decades as a scientist in biotech, vaccines, gene therapy and drug discovery, Shiv has been involved in partnering, managing large alliances and leading search and evaluation efforts for Sanofi's R&D for nearly 15 years. He is based in Bridgewater, NJ and manages an international team based in the US, France, UK and Germany.



• Sree Kant, Executive Director, Strategy, External R&D Innovation, Sanofi

Sree Kant is the Head of Strategy for Pfizer's External Science & Innovation group, leading partnering strategy across different therapeutic areas/technologies and geographies. He is focused on innovative partnerships, especially in the early stages with different partners (VC, biotech, academia, and foundations) to drive emerging science and breakthrough technologies. Before joining Pfizer, he was a Principal at the Boston Consulting Group advising large pharma and biotech on R&D strategy as well as large M&A. Sree has also worked with two healthcare startups and a generic pharmaceutical company in India and the UK. He has an MBA from the Indian Institute of Management, and an MPH from the Harvard School of Public Health.

10:00 - 10:50 AM WHY NYC? WHY NOW?









• Carlo Yuvienco, Senior Project Manager, New York City Economic Development Corporation



Dr. Carlo Yuvienco is a Senior Project Manager at the New York City Economic Development Corporation, the City's official economic development body, charged with using the City's assets to drive growth, create jobs, and improve quality of life. He is specifically dedicated to the strategy efforts behind LifeSci NYC, the City's \$500M initiative to support the growth of the life sciences sector in the five boroughs. He also oversees an existing portfolio of infrastructure and entrepreneurial training programs on behalf of the City, including NYC Entrepreneurship Lab, SBIR Impact NYC, Harlem Biospace, and the Early Stage Life Sciences Fund. Before his time at NYCEDC, Dr. Yuvienco developed blood filtration technologies for Pall Corporation Life Sciences. He holds a B.E. in Chemical Engineering from the Cooper Union for the Advancement of Science & Art and a Ph.D. in Biomedical Engineering from NYU.



• Blake Stevens, General Manager-LaunchLabs, Alexandria Venture Investments

With a background in entrepreneurship, venture investing, and scientific discovery, Blake specializes in working with early-stage companies. Blake uses this experience to accelerate the development of companies in his role as the General Manager of Alexandria LaunchLabs, the premier life science start-up platform in New York City. Prior to joining Alexandria, Blake served as Vice President of Harris & Harris Group, Inc., an early-stage venture capital firm, and was on the initial team at HZO, Inc., a startup focused on environmental protection of electronics. At HZO, Inc., he lead their efforts in R&D, commercialization and technical business development. Blake has also worked as the acting COO of TARA Biosystems, Inc. and sat on the Board of Directors of Promuc, Inc.; Interome, Inc.; and Synglyco, Inc. He holds degrees in Materials Science and Engineering from Cornell University (B.Sc.) and Northwestern University (Ph.D.) and a Certificate in Management for Scientists and Engineers from the Kellogg Business School.



• Eva Cramer, President, Downstate Biotech Incubator & BioBAT, NY Science & Technology Center

Eva Cramer, Ph.D., is a Distinguished Service Professor of Cell Biology, Vice President for Biotechnology and Scientific Affairs at SUNY Downstate Medical Center, and President of the Downstate Biotechnology Incubator and BioBAT at the Brooklyn Army Terminal. She received her Ph.D. from Jefferson Medical School and completed her postdoctoral training at the College of Physicians and Surgeons of Columbia University. Dr. Cramer has published numerous research articles and book chapters in the area of inflammation, was awarded a patent, and received grants from Federal and private agencies. Dr. Cramer has spearheaded efforts to establish the biotechnology industry in Brooklyn. She has raised over \$90 million from City, State, and Federal governments to build the Downstate Biotechnology Incubator and to develop BioBAT at the Brooklyn Army Terminal for biotechnology expansion and manufacturing. In recognition of her work, she received the Leadership in Urban Health Award from the Arthur Ashe Institute for Urban Health, the Partners in Leadership Award from the Research Foundation of the State University of New York, and the Chancellor's Award from the State University of New York. In addition, she has been designated a Distinguished Service Professor, one of the University's highest honors.



• Kate Merton, Site Head - JLABS @ NYC, Johnson & Johnson Innovation

Kate Merton is Head of Johnson & Johnson Innovation, JLABS @ NYC. Kate has over 15 years of experience working across the Healthcare industry starting in R&D before moving onto roles in in Marketing, Business Development, External Alliances, Medical Affairs, Health Outcomes and most recently Disruptive Innovation. During her career Kate has been part of teams that have discovered new drugs, worked to develop and gain approval for blockbuster diabetes products and is passionate about being part of the future of healthcare where science intersects with the rapid advancements in health care technology. Kate received her undergraduate degree in Pharmacology & Toxicology from King's College London, holds a PhD in Pharmacology & Toxicology from University of California, Irvine Medical School and received her MBA from the Fugua School of Business at Duke University.



• Mary Howard, Program Manager, ELabNYC

Mary Howard is the founder of Design Technologies, Program Manager for ELabNYC, Next Milestone and ABCT programs. A serial entrepreneur, Mary is proud to help the researchers who seek to bring their inventions to market while helping build the economies of local communities. Design Technologies programs are tightly integrated into the community of academic research institutions, hospitals, clinicians, pharma, law firms, accountants, CRO's, policy makers, incubators and government. The community is activated and engaged to help build early ventures. Design Technologies programs have helped launch and build more than 200 ventures in the Metro area in the past ten years.

11:00 - 11:50 AM Angel Investors

SPONSORED BY






• Yaniv Sneor, Founding Member, Mid Atlantic Bio Angels (M)

Yaniv Sneor is a (reformed) physicist, who made the transition into the business world after being bitten by the entrepreneurial bug. Yaniv is one of the founders of MABA – Mid Atlantic Bio Angels (bioangels.net) a life science angel investor group. MABA also orchestrates regular life science pitching events (1stpitchlifescience.com), which began in NYC and have since expanded to other states. Yaniv has been involved in founding, growing, managing and re-engineering companies for the past 25+ years, in multiple industries. He ran companies of different sizes and at different life-stages, led re-structuring activities, purchased and sold multiple companies, and negotiated and integrated joint ventures and strategic relationships. Through his consulting practice (Blue Cactus Consulting), Mr. Sneor assists companies with strategy, execution and technology commercialization.



• Jennifer Seibert, Managing Director, Golden Seeds

Jennifer Seibert is an experienced entrepreneur and angel investor in life science technology and related business and financial matters. Jennifer is a Managing Director of Golden Seeds, ranked by the Angel Capital Association as the most active investment groups in early stage start-ups. She has 20+ years' experience in pharmaceutical and diagnostic product development, sales/marketing, licensing & M&A for biotech companies and employers YM BioSciences (Gilead), Univ. Chicago, Abbott Laboratories, Amgen Inc., and Biosource International (Invitrogen). She earned MBA in Finance from Northwestern University, M.Sc. in Biochemistry from Drexel University and B.S. in Chemistry from University of Delaware.





Currently Mr Dixon is Director of the Wafic Said Molecular Cardiology Research Laboratories, Texas Heart Institute, Houston, Texas. In his current role I am involved in discovery and development of small molecule, gene and cell therapies for heart, lung and vascular diseases. Our department has a large medicinal chemistry group, which has successfully produced novel drug candidates. Over his career, he has been involved in most aspects of pharmaceutical and biotechnology research and development. Formerly, He was a Founder, Director, and CSO of Encysive Pharmaceuticals (ENCY). Prior to that, he held various management positions, including head of the molecular biology department at Merck and Co (MSD). He obtained a B.S. in Microbiology and Biochemistry from Texas A&M University, a Ph.D. in Virology from Baylor College of Medicine and conducted postdoctoral research at Johns Hopkins University School of Medicine in the laboratory of Dr. Daniel Nathans, the 1978 Nobel Laureate in Medicine. His basic research efforts focused on the molecular biology and pharmacology of intracellular signaling and cell trafficking. They were the first group to clone and characterize a G-protein coupled receptor, the beta2 adrenergic receptor (resulted in 2012 Nobel Prize in Chemistry to Kobilka and Lefkowitz), and they continue to focus on developing drugs to modulate various signaling pathways.

• Victoria Pettibone, Managing Director, Astia Angels



Victoria is Managing Director of Astia, an organization that levels the playing field for women entrepreneurs by providing access to capital, expertise and networks for the high-growth companies they run. She manages the global Astia Angels investor network, curates deal flow, executes investments and manages the portfolio. Since joining Astia and overseeing Astia Angels' investment activity, the group has gone from two investments to over seventy, in all sectors and geographies. Victoria also orchestrates Astia's global expert sift screening process to ensure continuous best-in-class deal flow for Astia and regularly works with entrepreneurs to support them through the screening and funding process. Victoria is herself an active investor and advisor in the innovation economy with a personal investment portfolio of thirteen (and counting) women-led companies across multiple industries ranging from medical device to software to clean tech. Victoria brings an entrepreneurial background to her work at Astia, as the former founder of a social enterprise in the media space. For her work focused on empowering women and girls in media, Victoria was recognized as an "Action Figure" in Women's Health Magazine (2007), received The Avon Hello Tomorrow Fund Award (2007), the Harlequin More than Words Award (2010) and was named one of "25 Visionaries Changing the World" in UTNE Reader magazine (2010).

• Wei Tao, Member, Sand Hill Angels



Wei Tao, Ph.D., is a Silicon Valley based angel investor focused on early stage life science and high-tech companies. He is an active member of several leading angel investment groups, such as Life Science Angels (LSA), Sand Hill Angels (SHA) and HealthTech Capital. He co-chairs the LSA Bio/Genomics/Diagnostics Committee and is a member of SHA Deal Sourcing Committee. Wei's extensive investment interest ranges from therapeutics to genomics, from diagnostics to digital health, from nanotechnology to drone technology and from artificial intelligence to virtual reality. Of his particular personal interests is to support advancement in cancer diagnostics and therapeutics. He successfully led and participated in numerous angel deals which subsequently received well over \$100 M follow-on venture capital investments. Wei serves on the Board of Directors of several early stage companies. Prior to his angel investment career, Wei spent over 15 years involved in genomics technology development and application in Boston, MA.





SPONSORED BY





ullet Ikechukwu Oji, Business Development & Licensing, Bayer Healthcare $\langle \mathbf{M} \rangle$



Ikechukwu (Ike) Oji is originally from Houston, Texas where he studied public health at the University of Houston. He then matriculated into the pharmacy program at Howard University College of Pharmacy and obtained a Doctorate of Pharmacy degree. Ike currently works at Bayer Healthcare as a Business Development & In-licensing Associate where he has led and supported key commercial activities (e.g., opportunity sourcing and due diligence) in various therapeutic areas, such as, Oncology, Women's Healthcare, Cardiovascular Disease, Nephrology, and Rare Diseases.



• Daniel O'Connell, Investment Manager, Arix Bioscience

Daniel has over 10 years' of experience in healthcare. Daniel joined Arix Bioscience from OrbiMed Advisors, where he played key roles across investments in both biotherapeutics and medical devices. Investments he has supported include CardiAQ (acquired by Edwards), Civitas Therapeutics (acquired by Acorda), Relypsa (acquired by Galenica), Cynapsus (acquired by Sunovion), as well as other public and private companies. Prior to OrbiMed, Daniel was the Associate Director of Cardiovascular Research at Arisaph Pharmaceuticals where he was responsible for pre-IND discovery and development for programs in lipid modulation. He received his MD and PhD in Biochemistry from Tufts University School of Medicine, and has undergraduate degrees in Mathematics and Chemistry from MIT.



• Diyong Xu, Senior Associate, OrbiMed Advisors

Diyong Xu joined OrbiMed in 2012 and is an Senior Associate on the Private Equity team covering venture capital investments in biotech, medical device and diagnostics companies. Prior to joining OrbiMed, Mr. Xu worked for Lazard in Healthcare Investment Banking Group, where he focused on M&A, financing and strategic advisory for biotech, diagnostics and pharma clients in U.S., Japan and E.U. Mr. Xu earned his M.S. degree in Management Science and Engineering from Stanford University and M.S. degree in Molecular and Cellular Biology from Dartmouth College. He holds a B.S. degree in Biology from Zhejiang University in China.



• Jonathan Mandelbaum, Principal, Accelerator Corporation

Jonathan Mandelbaum is a Principal at Accelerator Corporation where he is directly involved in all aspects of company building activities, including deal sourcing, due diligence and portfolio company operations. Prior to joining Accelerator in 2015, Jonathan worked in the oncology drug discovery unit at Millennium: The Takeda Oncology Company, where he was a bench scientist leading several early target pipeline projects, and also worked with the business development group evaluating external early-stage opportunities. He also performed his postdoctoral work at Millennium, supporting a late-stage preclinical drug discovery program. Jonathan obtained his Ph.D. from Columbia University with a focus on cancer genetics and lymphoma biology and received a B.Sc. in Biology from McGill University.



• Scott Weiner, Partner, Pappas Ventures

Scott is currently a Partner at Pappas Ventures, a life sciences focused venture capital firm based in North Carolina. Prior to joining the firm in 2006, Scott was an investment manager and research analyst at Silverback Asset Management's life science fund where he focused on healthcare securities investing. Before joining Silverback, he spent three years at Chicago Growth Partners focusing on healthcare venture investments, and previous to that, he spent three and a half years in investment banking at Lehman Brothers where he worked in New York, London and Hong Kong.

2:00 - 2:50 PM FAMILY OFFICES

SPONSORED BY





• Ron Paliwoda, Founder & President, The Paliwoda Group (M)

Ron Paliwoda is an accidental entrepreneur and seasoned investor, primarily through the Ventures arm of The Paliwoda Group, the firm he founded over 20 years ago. The firm's evergreen Health Tech Fund targets early-stage innovation that reduces costs to healthcare consumers, including projects that promote cost transparency to help consumers make more informed decisions in selecting service providers; that weave raw data streaming from remote patient monitors into insight about one's health and fitness (i.e. BioArray); and innovations at the intersection of molecular diagnostics and computational biology that use machine-learning tools to better understand complex disorders (i.e. Genotype Diagnostics). Ron actively advises entrepreneur leaders working to solve care and education challenges at underserved communities, and is a passionate advocate of local working environments where startups are nurtured and high-potential teams can excel.





Chuck's grandfather, Eugene W. Stetson, started the Stetson Family Office shortly after he personally led the buyout of The Coca-Cola Company through a public offering in August 1919 by the Guaranty Trust Company of New York, where he subsequently served as Chairman. At his death, Eugene was Coca-Cola's longest serving member of the Board and member of the Executive Committee. Chuck, the third generation running the family office, is an entrepreneur, venture capitalist, and philanthropist. The Stetson Family Office started Healthcare Impact Foundation, a 501-c-3 organization, in 2017 to bring capital and management expertise to life science companies at all stages and to build and maintain an efficient life science eco-system composed of R&D facilities, incubation facilities, venture capital investors, family office investors, and networks of experts in science, management, industry, reimbursement and public policy. Stetson Family Office is setting up a Global Family Office BioForum with family offices around the globe working closely with their local healthcare innovation. Family Offices are responding with excitement. Insead School of Business of Singapore at their 3rd Asian Family Office Day in 2015 had Chuck as their featured luncheon speaker.

• Kevin Schimelfenig, CEO & Managing Partner, McGeever



Kevin Schimelfenig is the Founder and Managing Partner of McGeever, LLC, a family office positioned to establish, administer and govern the financial and philanthropic values and goals of the family. McGeever's investment portfolio includes but is not limited to; Healthcare, Real Estate, Energy, and Information Technology. Through McGeever, Kevin participates in investments with multiple Angel Funds and is a limited partner with Private Equity firms on the East and West Coast as well as has affiliations with well-known medical device and diagnostic institutions across the United States. In addition, Kevin is acting President and CEO of SalesForce4Hire, McGeever LLC's wholly owned subsidiary. SalesForce4Hire partners with medical device, diagnostic, pharma/biotech and information technology companies and their investors to provide strategic models and solutions for commercialization. SalesForce4Hire has played lead roles in the successful implementation of custom sales solutions within leading companies on a global scale. Kevin's educational background includes a B.S. in Business Administration from Marywood University and extensive training in the Diabetes Program at Konkuk University Hospital in Seoul, South Korea. Kevin was recognized as a North Carolina top 50 Entrepreneur and has been an invited speaker for prominent organizations across the nation including JPMorgan/OneMedForum, AdvaMed, and Angel Capital Association.

• Mark Groner, Vice President, Sopris Capital



Mark Groner joined Sopris Capital in 2010 and is a Vice President. He has been involved in principal investing and investment banking since 2004. Prior to graduate school, Mr. Groner was an Associate at Linden LLC focusing exclusively on buyout investments in the healthcare industry. Mr. Groner began his career in the Investment Banking Division of Citigroup Global Markets, where he focused on mergers and acquisitions and financing transactions in the industrial, consumer, and automotive industries. Mr. Groner received a B.S. in Finance from Indiana University's Kelley School of Business and an M.B.A. from The University of Chicago's Booth School of Business.

• Sherry Grisewood, Chief Investment Officer, FoxHill Asset Management



Sherry has over 30 years' experience as a Wall Street professional in investment banking, advisory and research capacities across a wide variety of equity investment and corporate-directed advisory activities, primarily for early stage life science, med-device and related technology companies. She has participated in over 75 transactions involving initial public offerings, secondaries, private placements and M&A. Through her extensive corporate and academic interactions, Sherry has developed particular focus in therapeutic areas where there is an intersection of technologies such as regenerative medicine, nucleic acid-based technologies, immunotherapy and therapeutic medical devices that are being developed by US and ex-US life science companies. Sherry has been active at the Board level for several early stage life science and medical device companies over the last 20 years, and currently chairs the Audit Committee and is a member of the Compensation Committee for Tapimmune, Inc., a NASDAQ-listed cancer immunotherapy company and is a member of the Board for Mobitech Regenerative Medicine, Inc., an early stage orthopedics device company. She holds a Bachelor of Science degree with Highest Honors from Ramapo College of New Jersey and the Chartered Financial Analyst designation.

3:00 -3:50 PM CORPORATE VENTURE CAPITAL





TRACK 1 PANELISTS



ullet Elaine Jones, Vice President, Venture Capital, Pfizer Venture Investments $\langle {f M}
angle$



Elaine V. Jones, Ph.D. is currently a Vice President, Venture Capital, at Pfizer Venture Investments. Since joining the team in 2008, she is responsible for making and managing venture investments for Pfizer and currently oversees the PVI investments in Autifony Therapeutics Ltd., Blade Therapeutics, Mersana Therapeutics, MISSION Therapeutics, Nimbus Therapeutics LLC, Quartet Medicine, Second Genome, and Storm Therapeutics. Elaine brings 18 years of venture capital experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development to the PVI team. Dr. Jones also manages Pfizer's R&D Innovate initiative which invests in early stage biotechnology companies that are closely aligned with Pfizer's R&D strategy. In this role, she serves on the boards of Arrakis and NextCure. Prior to joining Pfizer, Dr. Jones was a General Partner with the venture fund, EuclidSR Partners. There, she was responsible for the fund's investments in Acurian, Fluidigm, InnaPhase and Targacept. Dr. Jones began her private equity career in 1999 at S.R. One, GlaxoSmithKline's venture fund, where she managed investments including Adolor, Avantium, Nucleonics, Scynexis and Vicuron.

• Charles Kunsch, Director, AbbVie Ventures



Chuck has over twenty five years of experience in biomedical R&D, business development and corporate venture capital investing. Since 2013, Chuck has been a member of AbbVie's Venture team and is based in Cambridge, MA where his focus is on early-stage investments in life sciences. Chuck is responsible for sourcing, evaluating and transacting venture investments and is a board observer to several AbbVie portfolio companies. Prior to joining the Ventures team, he served as a Director in Abbott's Global External Research organization where he was responsible for the identification, assessment, and development of early-stage partnerships across Abbott's therapeutic areas. Before joining Abbott in 2009, he served as Vice President of Discovery at AtheroGenics, Inc leading teams that brought several programs into clinical development for cardiovascular disease, diabetes, rheumatoid arthritis and asthma. Before joining AtheroGenics, Dr. Kunsch started his career in biotech as one of the first scientists with Human Genome Sciences where he led a team of scientists to fully sequence the genomes of several medically important bacterial pathogens.

• Claire Leurent, Bio Sector Investment Director, Samsung Ventures America



Claire Leurent is a biologist by training. She earned her PhD in molecular and cellular biology at the Institute of Genetics, Molecular and Cellular Biology (IGBMC) in Strasbourg, France. She then joined the pharmaceutical industry to work on drug development in several capacities over the past 13 years. Initially on late phase development with Wyeth Pharmaceutical (Paris office) as a Senior Clinical Scientist contributing to global phase 3 registration trials, NDA dossier submission and new product launch. Then on early stages with Pfizer Neuroscience out of its R&D headquarters in Groton CT, and later from Pfizer's Kendall Square campus in Cambridge MA, where she led teams in designing and conducting clinical plans from First in Human to Proof of Concept studies for small molecules, biologics and digital biomarker technologies. Over the years, Claire developed a passion for the business aspects of innovation, obtained her MBA from MIT Sloan and recently joined Samsung Ventures as Investment Director for healthcare, biotech and life science.

• Eric Feinstein, Investment Director, Northwell Ventures



Currently, Eric is an investment director at Northwell Ventures, (the corporate venture arm of Northwell Health) and spends the bulk of his time running investment activities for the venture capital fund, driving portfolio growth, and commercializing new, innovative healthcare concepts within Northwell. He brings a wealth of experiences in the venture and private equity worlds, having made investments into and serving on the boards of several later-stage medical device and healthcare service businesses, as well as running long-term revenue growth engagements for consumer-focused companies. Eric has also served in an operational capacity as the interim CEO for Healthflix, a healthcare IT start-up focused on patient engagement. Current investments include: Conversa Health; Purple Sun; & Clarapath. His functional investment and portfolio experiences include: new market and product entries; overall growth strategies (organic & inorganic), sales channel transformations, market research and sizing, consumer behavior and segmentation; growth oriented change management, & M&A. Prior to Northwell Ventures, Eric was a Director of the Northeast Transaction Advisory and M&A group at RGP. Prior to that, he was a Principal at BSV Consulting Group, a boutique venture capital consulting firm focused on driving top-line revenue growth and performing transaction due-diligence.



4:00 - 4:50 PM VENTURE PHILANTHROPY

SPONSORED BY









In this new role John is charged with meeting the ever-increasing demand for research funding, building brand equity, and exploring investments with industry partners for AGCT, which exclusively supports research in genetic, cell and immunotherapeutic approaches to improve outcomes for all cancers. John served as President and CEO of the Leukemia & Society, an international health agency. He drove LLS's long-range strategic plan with a focus on broadening its base of support and diversifying its revenue sources. John first joined LLS in 1995 as Senior Vice President of Finance and Information Technology. Then, as Executive Vice President of Strategic Alliances and New Business Development, he designed and implemented LLS's Co-Pay Assistance Program, which has provided more than \$200 million to patients. He also oversaw the international merger that created LLS Canada. John directed the launch of "Someday is Today," the branding platform that illuminates how LLS is changing the landscape of cancer. He guided the expansion of the Therapy Acceleration Program, embracing a venture philanthropy approach. John has spoken at congressional events in Washington, and to the international business community. He has been published in numerous journals.

• Andres Hurtado-Lorenzo, Director of Translational Research, Crohn's and Colitis Foundation



Dr. Andres Hurtado-Lorenzo is the Director of Translational Research at the Crohn's and Colitis Foundation. He is responsible for planning and oversight the Foundation's translational research portfolio that funds several research initiatives. These initiatives aim to identify opportunities to translate observations in the laboratory and clinic into interventions that reach and benefit patients; from therapeutics and diagnostics to medical devices and procedures. The Foundation's initiatives include microbiome and genetics initiative, RISK stratification, environmental triggers, and a venture philanthropy initiative focused on accelerating product discovery and development through entrepreneurial investing. Dr. Hurtado-Lorenzo has extensive drug discovery and development experience gained both in pharmaceutical and biotechnology industry. As industry scientist he led research and development programs for neurological and rare diseases at Wyeth, Pfizer and Proteostasis Therapeutics, all the way from discovery to early clinical development. He obtained his Ph.D. in Molecular Medicine from the University of Manchester in the UK, where he contributed to pioneer the research on viral gene therapy for neurodegenerative diseases. He completed his postdoctoral work at Harvard Medical School, Massachusetts General Hospital and Columbia University, where he conducted groundbreaking research focused on molecular mechanisms of autophagy and other protein degradation pathways and their role in health and disease.

Alyssa Reimer, Associate Director, Research Partnerships, The Michael J. Fox Foundation for Parkinson's Research



Alyssa N. Reimer joined The Michael J. Fox Foundation for Parkinson's Research (MJFF) in 2015. In her current role, Alyssa manages data and biospecimen resources from MJFF-sponsored and -funded clinical trials. She leads a data curation, harmonization, and centralization initiative aimed at establishing a platform for making previously siloed datasets widely available and breaking down barriers to clinical trial data analysis. Alyssa leads the newly developing regulatory engagement strategy for effective collaboration with regulators in response to the evolving Parkinson's disease (PD) research landscape. Prior to joining MJFF, Alyssa was an Intern at Mesoblast, a pharmaceutical company focused on using stem cell research to cure human disease. Alyssa had also worked in several organic synthesis laboratories as an undergraduate. Alyssa graduated from Harvard University with a BA in Chemistry.

Kenneth LaMontagne, VP of Research, Leukemia & Lymphoma Society



Ken is an experienced leader with broad knowledge of the healthcare industry. Expertise in Oncology, Immuno-Oncology and Cell & Gene Therapies (CGT): includes research and development, clinical and commercial responsibilities. Ken has had roles including Oncology translational science, diagnostics, new products and business development and licensing (BD&L). Ken received his Ph.D. from SUNY at Stony Brook, while his PhD dissertation was done at Cold Spring Harbor Laboratory in New York. Ken was a post-doctoral fellow (former Career Development Award recipient from the Leukemia Society of America) in the lab of the late Dr. Judah Folkman, Harvard Medical School. Upon completion of his training, Ken ventured into the Pharmaceutical sector with increasing roles at both Johnson & Johnson and Novartis. Ken recently completed an MBA from the Executive program at Rutgers Business School. Ken is now Head of the Therapy Acceleration Program (TAP) at the Leukemia & Lymphoma Society.

Michael Batten, Director, Strategic Partnerships, JDRF T1D Fund



Michael Batten, M.D., M.B.A., is a director for JDRF T1D Fund where he facilitates venture creation and syndicated venture investments focused on translating innovative Type 1 Diabetes research into lifesaving therapies for T1D patients. Previously, Dr. Batten invested in healthcare companies as a portfolio manager at Merrill Lynch and a member of the investment team of the Caxton Health Holdings. Prior to his investing roles, Michael was a member of Pfizer's Business Development group where he led multiple transactions and was instrumental in the creation of Pfizer Venture Investments, the strategic venture capital arm of Pfizer. Dr. Batten received his B.S. in Mechanical Engineering from N.C. State University, M.D. from U.N.C. – Chapel Hill, trained in Ophthalmology at NYU, and M.B.A. from Wharton.





TRACK 2: **DEVICE, DIAGNOSTIC & HCIT INVESTOR PANELS**

SPONSORED BY





Track 2

Moderator & Panelists

9:00 - 9:50 AM

PAYER & PROVIDER VENTURE FUNDS

The Technologies That Hospital Systems & Health Plans Are Seeking

- Brent Stackhouse, Vice President, Mount Sinai Ventures (M)
- Jacob Brody, Founding Partner, Helpful Capital
- Jonathan Gordon, Director, NewYork-Presbyterian Ventures
- Michael Thomas, Director, IPHA, Inova Strategic Investments
- Kelly Krajnik, Senior BD Manager, Mayo Clinic Ventures

10:00 - 10:50 AM

COLLABORATIVE VIRTUAL PHARMA

New Development Models to Fight Diseases with No Treatment or Cure

- Colin Widen, CEO, Boston Innovation Capital (M)
- Adriann Sax, Entrepreneur in Residence, Fortress Biotech
- Annette Bakker, President & CSO, Children's Tumor Foundation
- Bill Kohlbrenner, CSO, Life Science Nation
- Richard Soll, Senior VP, Research Service Division (RSD), WuXi AppTec

11:00 - 11:50 AM

HEALTHCARE IT INVESTORS

Leveraging Software to Lower Costs and Improve the Quality of Care

- Ying Tam, Managing Director, Health Venture, MaRS Discovery District (M)

- John Gu, Vice President, Spring Mountain Capital
- Scott Kaplanis, Partner & Portfolio Manager, Epic Capital Management
- Tom Foley, Director, WW Health Solutions Strategy, Lenovo Health

1:00 - 1:50 PM

MEDICAL DEVICE INVESTORS

Investing in **Novel Engineering**

- Sam Ifergan, President & CEO, iGan Partners (M)
- Ibraheem Badejo, Sr. Director, New Ventures, Johnson & Johnson Innovation
- Katherine Parra Moreno, Vice President, Epic Capital Management
- Lu Zhang, Managing Partner, NewGen Capital
- Seth Tropper, Global Open Innovation, Digital & Devices, I&D Operations, Bayer Consumer Health

2:00 - 2:50 PM

Due to the popularity of the family office panel in track 1, there's no panel scheduled during this time slot

3:00 - 3:50 PM

TALES FROM THE ROAD

Successful Biotech & Medtech **CEOs Share Their Story**

- Michael Tippie, CEO, Lipidomics (M)
- Chicuong La, Founder & CEO, Focal Healthcare
- Ilana Odess, CEO, Woven Orthopedic Technologies
- Jim Iversen, CEO & COO, Sen-Jam Pharmaceutical
- Seth Harlem, CEO & Co-founder, Taithera

4:00 - 4:50 PM

DIAGNOSTICS INVESTORS

New Generation of Technologies Enabling Personalized Medicine

- Tom Miller, Founder & Managing Partner, GreyBird Ventures
- Andy Cosgrove, Head of Strategic Alliances, Sr. Director BD North America, WuXi NextCODE
- Bob Williams, President, IVMatters
- Drew Taylor, Lead Medical Researcher, Epic Capital Management
- John Steuart, Managing Director, Steuart Ventures



M Moderator



9:00 -9:50 AM PAYER & PROVIDER VENTURE FUNDS

TRACK 2 PANELISTS









Brent Stackhouse is the Vice President of Mount Sinai Ventures, the venture investment arm of the Mount Sinai Health System in New York City. His responsibilities include diversifying the portfolio of strategic investments to enhance Mount Sinai's transition to population health management. He represents Mount Sinai on the board of several portfolio companies, including ambulatory surgery and urgent care centers. He is experienced in public health and health information technology, and serves on Mount Sinai telehealth strategy committee, Mount Sinai Health Partners board of managers, and the Junto Collaborative for health innovation. Prior to joining Mount Sinai, Brent was the Executive Director of Strategy at the Primary Care Information Project at the New York City Department of Health and Mental Hygiene. In this role, Brent oversaw the strategy and operations for the bureau responsible for expanding the adoption of electronic health records and the use of health information technology for care coordination and quality improvement across New York City. He was responsible for developing and managing programs for key stakeholders including Accountable Care Organizations, health systems, insurance companies, as well as State and Federal partners. Prior to his career in health care, Brent worked in investment banking and commercial real estate finance. He has a Bachelor in Science from the Walsh School of Foreign Service at Georgetown University.



• Jacob Brody, Founding Partner, Helpful Capital

Jacob Brody is a Founding Partner at Helpful Capital, a platform investment firm where he invests in entrepreneurs building next generation platforms. He currently serves as a formal advisor to Expanding Capital (growth stage venture firm), Vast Ventures (early stage venture firm), Descartes Labs (geospatial analytics) and Abra (bitcoin based remittance platform). Jacob previously Co-Founded Benny, a freelancer finance and insurance startup backed by GV (Google Ventures) and other top tier investors. Throughout his career, he has led investments in over 30 seed through growth stage startups across consumer, fintech, insuretech, healthcare, enterprise software, hardware and adtech. In his free time he likes to write nerd/startup themed raps and hang out with his wife Lauren and baby boy Bowie.



• Jonathan Gordon, Director, NewYork-Presbyterian Ventures

Jonathan Gordon is Director of NYP Ventures, the strategic venture capital arm of New York-Presbyterian, where he is responsible for managing the hospital's venture investment fund, building strategic partnerships and managing the hospital's IP portfolio. Previously, Jon was a Director in the Hospital's Office of Strategy, where he worked on projects ranging from launching the hospital's Medicare accountable care organization to building a telehealth program. Jon is also Director of the Health Policy Center at New York-Presbyterian, which advocates for the role of Academic Health Centers in developing solutions for the American healthcare system. Jon serves on faculty at Weill Cornell Medicine, and teaches about leading healthcare transformation. Prior to joining NYP, Jon helped found and served as Chief Operating Officer of EveryDay Medical, an e-commerce-based provider of durable medical equipment. Jon is a member of the Hermann Biggs Society, a mentor for the German Accelerator and Blueprint Health incubators, and a Director of Costs of Care, a not-for-profit dedicated to increasing cost awareness among clinicians. Jon holds a BA cum laude from Princeton University and an MBA with honors from Columbia Business School.



• Michael Thomas, Director, IPHA, Inova Strategic Investments

A veteran med-tech CEO, Michael Thomas is Director of the Inova Personalized Healthcare Accelerator. Prior to Inova, Michael was CEO of Appian Partners, an Annapolis, MD-based life sciences consulting practice. His med-tech experience spanned several early stage, growth stage, and turn-around ventures as CEO of Appian Partners, ReGear Life Sciences, NuSomnea, Tanzen Medical, Appian Medical, iSonea, and Sleep Solutions. Mr. Thomas was founder and CEO of Appian Medical, a digital health firm that developed an algorithm to diagnose Obstructive Sleep Apnea. Mr. Thomas spent 2.5 years as CEO of iSonea Ltd (ASX:ISN), a publicly traded global, asthma digital healthcare company. He raised \$25MM for iSonea and increased the company's market capitalization from \$4MM to \$250MM. He is a member of the Board of Directors for Circadiance, a specialty CPAP mask manufacturer. Earlier in his career, Thomas was CEO of Sleep Solutions, a VC--backed medical device manufacturer. He raised over \$50 million in VC funding. Prior to joining Sleep Solutions, Thomas was EVP of Sales and Marketing for National Sleep Technologies (NST), where he led acquisitions of more than 80 sleep labs, making NST the largest sleep testing company in the US. NST was later sold to GE Medical.



• Kelly Krajnik, Senior BD Manager, Mayo Clinic Ventures

Kelly Krajnik is a Senior Business Development Manager who has been with Mayo Clinic Ventures since 2006. She is responsible for seeking out and developing new business and technology commercialization opportunities by working with Mayo Clinic staff and external companies, entrepreneurs, and investors. Prior to joining Ventures, Kelly served on a Mayo Clinic Institutional Review Board and worked as a Senior Research Technologist developing and conducting microarray expression analysis protocols in support of Mayo Clinic research programs. Kelly received a B.S. in Microbiology from UW - La Crosse and her M.B.A. from the University of St. Thomas. She is also a registered Patent Agent with the USPTO.



10:00 -10:50 AM COLLABORATIVE VIRTUAL PHARMA



TRACK 2 PANELISTS



• Colin Widen, CEO, Boston Innovation Capital (M)

Colin Widen, registered representative, is a seasoned executive with 25 years of sales, trading and portfolio management experience in major investment banks. In 2001, Colin left the institutional world and founded W.A.M. Asset Management, a private equity fund of funds that focused on SBIC private equity funds. After selling the firm to a larger fund of funds, Colin joined Deutsche Bank where he led a team providing consulting services about alternative asset allocation strategies to family offices and smaller endowments and foundations. Colin is a registered representative and holds Series 7, 24, 63 and 82 registrations. His specialties include reconstructing hedge fund portfolios and analyzing private equity holdings.

• Adriann Sax, Entrepreneur in Residence, Fortress Biotech



Adriann is an Entrepreneur in Residence at Fortress Biotech, that forms subsidiary companies and finances promising drugs and technologies. For more than 25 years, Adriann has been has been a global biotech and pharmaceutical industry leader managing all stages of drug development, commercialization, strategic deal-making and partnerships. Prior to Fortress, Adriann was Executive Vice President, Chief Commercial Officer of Kadmon Corporation building and leading Kadmon's commercial organization, Kadmon Pharmaceuticals, from its inception in September 2010. Before Kadmon, Adriann was Executive Vice President, Business Development and Strategic Planning at King Pharmaceuticals where she led many profitable transactions in addition to creating and implementing King's Corporate Strategy for Growth in 2005, contributing to the company's overall success and ultimate sale to Pfizer in 2011. After starting her career as a sales representative at Sterling Drug, Adriann progressed through a series of management and executive roles with established biopharmaceutical companies including Roche, BMS and Merck in commercial operations, strategy and business development. Although she's made many important contributions in the areas of oncology, transplantation and diagnostic imaging, her leadership of the global launches of ERBITUX® (cetuximab), ZENAPAX® (daclizumab) and VISIPAQUE® (iodixanol) are testimony to her unique abilities, commitment and tenacity to "make a meaningful difference for patients".

• Annette Bakker, President & CSO, Children's Tumor Foundation

Annette, a PhD in Biochemistry, has leadership experience in both the academic and pharma/biotech research enterprise in Italy, Belgium, France, and the USA. Intrigued by the observation that the path from great basic discoveries to equally great clinical benefit is bumpy and often inefficient, she joined the Children's Tumor Foundation (CTF) in order to try to smooth this path for neurofibromatosis, a rare genetic disorder. The team has built collaborative science networks, an open biobank, a centralized data hub at Sage, a patient registry, KOL networks, etc. Annette feels very strongly about involving the patient voice in every initiative since patients are partners rather than victims. She hopes that the new CTF enterprise will not only benefit patients with NF, but may be of value to the larger rare disease community.





Bill is Consulting Scientist for Boston Innovation Capital. His role at BIC involves technical vetting of potential clients and working with established clients to best position their early-stage companies for successful transactions with investors or large technology/pharma companies. Prior to joining BIC in 2014, Dr. Kohlbrenner was a director at AbbVie (Abbott pharma) where he was involved in identifying and pursuing external research opportunities and early-stage assets around the globe. This work included leading a global scouting team and conducting strategic assessments of early- and late-stage pipeline opportunities in multiple therapeutic areas. Earlier in his career, Bill led drug discovery research programs in several areas, including oncology, antivirals and antibacterials. As a director in the Cancer Research area, he was involved in the exploration of novel anti-cancer therapies and the identification of novel cancer targets. A major emphasis of this work was on the RNA therapy space and he led a major in-house research effort that was focused on the identification of nanotechnology-based carriers for the delivery of novel RNA cancer therapies. Bill was extensively involved in setting up and managing external collaborations with universities, research institutes and biotechs world-wide to support the projects he was leading. Bill has co-authored numerous research articles (~60) examining the fundamental aspects of various drug targets and the molecular basis of drug action.

• Richard Soll, Senior VP, Research Service Division (RSD), WuXi AppTec



Dr. Richard Soll is Senior Vice President, Research Service Division (RSD), at WuXi AppTec and leads the WuXi offices in Cambridge, Massachusetts and in Israel to bring WuXi's comprehensive platform of integrated R&D services closer to innovative companies and entrepreneurs in the world's two leading biotech hubs. Dr. Soll's contributions to drug discovery and development led to the discovery of the HCV breakthrough therapy elbasvir, the JAK2 inhibitor fedratinib, and more than 10 other clinical stage drugs. Dr. Soll has co-authored more than 100 patents and papers. Dr. Soll serves on the board of the Accelerator has been an SAB member to biotech companies and advisor to entrepreneurs. Prior to WuXi, Dr. Soll was CSO and VP of R&D at TargeGen where he led multiple clinical stage R&D programs. Dr. Soll founded the chemistry department at 3-Dimensional Pharmaceuticals as VP of Chemistry. Dr. Soll began his industry career at Wyeth Pharmaceuticals, and was trained as a synthetic chemist at Dartmouth and Harvard.



11:00 - 11:50 AM Healthcare it investors

SPONSORED BY





• Ying Tam, Managing Director, Health Venture, MaRS Discovery District



Ying Tam is a seasoned entrepreneur and business executive, and is currently Managing Director, Health Ventures, for MaRS, one of the world's leading urban innovation hub. MaRS works with a large network of corporate partners and venture funds to help entrepreneurs launch and grow the innovative companies that are changing the future. Ying has co-founded several start-up companies, including Mindful Scientific, a medical device company addressing concussion diagnostics and management, abridean (acquired by nCipher PLC), a software company developing application provisioning and identity management solutions, and i-HRx (acquired by Healthconnex), a digital health company focused on chronic disease management. He has significant strategic and functional experience with operating roles in a wide range of organizations, from early stage companies to major multi-national corporations.



• John Gu, Vice President, Spring Mountain Capital

John Gu is a Vice President in SMC's private equity group and has been with the firm since 2015. Mr. Gu was previously an Analyst at HealthCor Partners, a healthcare-focused growth-equity firm with approximately \$400 million of capital commitments. Prior to HealthCor Partners, Mr. Gu was an Investment Banking Associate at Citadel Securities where he focused on transactions in the healthcare and technology sectors. Mr. Gu graduated from Carnegie Mellon University with a M.S. in Electrical and Computer Engineering, a B.S. in Electrical and Computer Engineering and a B.S. in Economics.



• Scott Kaplanis, Partner & Portfolio Manager, Epic Capital Management

Scott joined Epic in early 2008 and has more than 12 years of Canadian capital markets experience. Prior to joining Epic, he worked as a research analyst at Macquarie Capital Markets Canada. Scott's investment background spans a variety of industries including healthcare, technology, energy services, industrials, transportation, and infrastructure services. He holds an HBA from the Richard Ivey School of Business, is a CFA Charterholder, and is a special adviser to The Funding Portal. He is also a Board member at Memex Inc. (OEE.TO)



• Tom Foley, Director, WW Health Solutions Strategy, Lenovo Health

Mr. Foley has over 30 years of experience in information technology. Major achievements in his career: lead collaborator to computerize UPS' 83 regional call centers, significant contributor in the roll-out of the first national wireless data networks. Health IT related achievements: President of iPatientCare (cloud based EHR), Patient Portal roll-out attacking over 15M users; led largest initial roll-out of direct messaging, 43,000 subscribers. In his current position with LenovoHealth, Foley's strategic thinking and innovative approaches across the wrist to cloud continuum is changing the way the market looks a value based care, connected health and virtual care models.

1:00 - 1:50 PM Medical Device Investors

TRACK 2 PANELISTS

SPONSORED BY





• Sam Ifergan, President & CEO, iGan Partners

Sam Ifergan is the President and CEO of iGan Partners, a Toronto-based venture group focused on healthcare IT, medical imaging devices, B2B SaaS, and data-driven technologies. He has over 20 years of entrepreneurial, technology and venture capital experience. Prior to founding iGan Partners, he co-founded several companies including Visualsonics, Tri-Link Technologies and Brighter Minds. He was also a strategy consultant with Mercer Management Consulting (now Oliver Wyman) where he advised Fortune 500 companies on corporate strategy. Additionally, Sam has held general management roles at NCR, where he led the deployment of enterprise-grade information technology systems. Sam holds an MBA from the John Molson School of Business and a Bachelor of Electrical Engineering from McGill University.



• Ibraheem Badejo, Sr. Director, New Ventures, Johnson & Johnson Innovation

Ibraheem (Ib) is Senior Director, New Ventures at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector. From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University. During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired. Ib received his BA degree in chemistry from Avila University. He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending.



• Katherine Parra Moreno, Vice President, Epic Capital Management

Katherine Parra Moreno joined Epic in 2015. She brings five years of capital raising and business development experience in the financial services industry to our team. Prior to joining Epic, Katherine was the Manager of Investor Relations at Sprott Inc., a Canadian investment firm with over \$7 billion in assets under management. Katherine has an Bachelor of Commerce Degree from the Ryerson Ted Rogers School of Management and she is a CFA level II candidate.



• Lu Zhang, Managing Partner, NewGen Capital

Lu Zhang is the Founding and Managing Partner of Fusion Fund (A.K.A. NewGen Capital). Prior to starting Fusion Fund, she was a Venture Partner at Fenox Venture Capital. She participated in over 20 investments and assist M&A of the portfolios. Lu was also the Founder and CEO of a start-up focused on non-invasive technology for the early diagnosis of Type II diabetes (acquired in 2012). Lu received her M.S. in Materials Science and Engineering from Stanford University and holds several patents. She is an advisor and mentor to several innovative programs and incubators in Silicon Valley. Lu has won numerous awards and is frequently invited to speak at events. She was awarded the Forbes US 30 under 30 & Featured as the Honoree of VC category. She was also awarded the Forbes Asia 30 under 30 of Finance category in the same year. She was recently awarded as the T&C 50 Modern Swans Influencer, representing top female entrepreneurs in US.



• Seth Tropper, Global Open Innovation, Digital & Devices, I&D Operations, Bayer Consumer Health

Seth Tropper joined Bayer Consumer Health in 2017 to lead digital and device efforts for global open innovation. Seth is a strategic-minded entrepreneur and innovator with 20+ year portfolio of success across technology commercialization and start-up ventures. Throughout his career, Seth has initiated, launched, and exited startup ventures; worked for large companies; and supported new venture efforts for universities. He has been a mentor and advisor for early stage companies and investment funds; with areas of expertise in Digital Health, Medical Device, Wearables/IoT, Media, Mobile, Data Analytics, and Technology Enabled Services. As co-founder & CEO of a wearables technology, coupled with a wellness and data analytics platform (Switch2Health) to impact user behavior towards lifestyle changes; Seth exited to a leading device and activity tracking company, Fitbit. Prior to Switch2Health, he was a founding partner of high-tech startup, PlasmaSol, acquired by Fortune 100 medical device maker Stryker Corp. Most recently, Seth was a management consultant working on the development and commercialization of biosignal emotion recognition technology; and also worked for Yahoo focused on 1) establishing partnerships with leading research universities to better address the future of the internet and technology; and 2) identifying technologies and companies, and performing due diligence for potential collaboration or acquisition. Earlier in his career, Seth held positions in software engineering and management for AT&T and IBM Global Services.



3:00 - 3:50 PM TALES FROM THE ROAD



SPONSORED BY





• Michael Tippie, CEO, Lipidomics (M)



Michael Tippie is the CEO of Lipidomics, Inc, focused on cosmetic solutions and pharmaceutical treatments for eczema. Michael has previously been a life science venture capitalist (Norwest Venture Partners, Medical Innovation Partners, Milk Street Ventures, ONAMI), a senior executive in early stage life science companies (TomegaVax, CNS Response, Avior Therapeutics, LifeSpan BioSciences, StressGen Biotechnologies, Tacora) and a research chemist in the pharmaceutical and diagnostics industry (Syntex and Syva Research). Michael has done strategic alliances with many pharma companies, as well as raising over \$300 MM in equity capital, including two IPOs to date. Michael holds an MBA from the Sloan School of Management at MIT, an MS in Chemistry from the University of Washington (with additional graduate work in Immunology, Proteomics and Genomics) as well as a BA in Chemistry from Reed College.



• Chicuong La, Founder & CEO, Focal Healthcare

Chicuong La is a seasoned executive in the field of medical devices with a strong expertise in medical imaging. Prior to founding Focal Healthcare in 2014, Chicuong was a key leader in three other early stage ventures, including serving as the VP of Business Development and the COO of Exact Imaging (formerly Imagistx), a prostate imaging company. He also served as the Managing Partner of Simulogic, a software company in applied medical research. In addition, Chicuong has extensive commercialization experience through work for two commercialization centers, including his role as Business Development Manager at the Robarts Research Institute, a world-renown medical imaging research center. In these positions he focused on identifying innovative ideas and creating strategic plans to transition these ideas from the lab into clinical use. His hands on experience in development of medical imaging devices and working with researchers has given him a strong understanding of the technical, logistical, financial and legal needs of Focal Healthcare. Chicuong has a PhD in Physiology and Biophysics and a Juris Doctor from Dalhousie University.



• Ilana Odess, CEO, Woven Orthopedic Technologies

Ms. Odess has spent her entire career within the healthcare & science industries and has held senior executive roles for multinational companies and start-ups such as Israel Chemicals, Johnson & Johnson, Advanced Stent Technologies, CID. As an operator, Ms. Odess is an expert in leading companies from concept to clinical application and has created multiple businesses acquired by multi-billion dollar medical device companies, negotiated over 30 worldwide partnerships, and commenced direct corporate operations in Israel for Johnson & Johnson. As an investor, Ms. Odess has led international medical technology investments and management buyouts for an international family office and led Johnson & Johnson's acquisition of two businesses. Ms. Odess has been recognized for her ability to create successful innovative solutions and has received both a Frost & Sullivan award for innovation and the state of Connecticut's "2014 Woman of the Year" award for Entrepreneurial Innovation and Leadership. Ms. Odess graduated with a BS in Biochemistry and an MBA from Bar-Ilan University.



• Jim Iversen, CEO & COO, Sen-Jam Pharmaceutical

Jim Iversen is a growth-focused Senior Executive and Board Member with more than 30 years of success spanning energy, transportation, distribution, enterprise, software, warehouse management, life science, consumer products, and engineering. Leveraging extensive experience in strategic, resourceful leadership, Jim is a valuable asset for small to mid-sized companies requiring expert assistance with business growth and development, evaluating and positioning selling, turnaround management, and strategic planning. His broad areas of expertise include business strategy, leadership training and development, company culture, and business growth. Throughout his executive career, Jim has held leadership positions with JMI Capital Group, Northern Reliability, M&I Strategic Partners, W&H Systems, Horizon Foods, and AL Systems. He is currently the CEO of JMI Capital Group, which provides companies with business strategy and M&A advisory services. In this role, Jim has been responsible for advising a leading Enterprise Resource Planning software company, resulting in a successful sale and a 25% IRR, and a leading supply chain company, resulting in a successful sale and 36% IRR. In a previous role as CEO of M&I Strategic Partners, which provides businesses with software solutions, Jim led the acquisition of AL Systems and Mincron Software Solutions, resulting in a significant increase in each company's revenue and EBITDA growth.



• Seth Harlem, CEO & Co-founder, Taithera

Seth Harlem is the Co-founder and CEO of Taithera, Inc. Seth is an entrepreneur and has brought several early stage companies & products to market. Seth also helped to establish the U.S. presence of a large (\$3+BN market capitalization) Chinese financial technology company, and ran business development for a New York based financial technology company. In addition Seth lived in China where he worked for General Motors in Shanghai and Liuzhou, China. Seth has also advised healthcare companies on fundraising and technology product development. Seth holds an MBA (with honors) from Columbia Business School.



4:00 - 4:50 PM DIAGNOSTICS INVESTORS

TRACK 2 PANELISTS

SPONSORED BY









After receiving a degree in Nuclear Engineering from the University of Massachusetts at Lowell, Tom studied Medical Physics at the Harvard/MIT Health Sciences and Technology joint program graduating with a Masters degree in 1982. During his academic career he worked at Los Alamos, the Swiss Institute for Nuclear Research (now the Paul Scherer Institute), Brookhaven National Laboratory, and the Massachusetts General Hospital as a research associate in radiation biophysics. Tom then joined Siemens Medical Systems where, after 9 years, he became the first non-German CEO of a German factory and business unit. He left Siemens after 15 years to become CEO of the global medical operations of Carl Zeiss. Completing a successful turnaround, he joined Analogic Corporation as CEO. After three years and a doubling of the stock price, Tom left to become CEO of LightLab Imaging, a start-up that he helped to establish. Completing a profitable sale of LightLab, Tom re-joined Siemens eventually serving as a member of the operating board of Siemens Healthcare and the CEO of Customer Solutions Division, responsible for 26,000 employees in over 130 countries. Tom co-founded GreyBird in mid-2013 with an investment focus on technologies enabling precision medicine diagnosis.



Andy Cosgrove, Head of Strategic Alliances, Sr. Director BD North America, WuXi NextCODE

Andy has a diverse 18 years of health care commercialization experience in Life Science, Clinician Engagement &Education, and Genomics. Andy's current role a WuXi NextCODE is focused on driving the sourcing, design, negotiation and management of alliances with channel, technology and other partners.





Bob is a veteran product development, strategic marketing and business development professional in the medical device industry. His professional experiences have primarily been in the diagnostic imaging, gastroenterology, interventional radiology and interventional cardiology market segments. IVMatters was recently founded in pursuit of providing advisory, strategic planning, product development, regulatory support and angel investment to early stage medical device companies. IVMatters currently represents clients in the diagnostic imaging and HIT space. IVMatters also has initiated a start-up product development effort for a disruptive, low cost, IV injection-infusion technology at the LaunchPad Long Island technology incubator in cooperation with the Biomedical Engineering Innovation Group at the University of Magdeburg, DE. Bob continues to be an active member of the Life Sciences Angel Network (LSAN) based out of New York City since its inception in 2010, serves on its screening committee, mentors entrepreneurs applying for funding and has personally invested in several of its portfolio companies. Prior to founding IV Matters, Bob has served in executive roles for Bracco S.p.A., ACIST Medical Systems, Inc. and Bracco Injeneering SA. During this tenure, he has initiated and supported numerous business deals and partnerships for Bracco's global medical device businesses. Other career highlights include product development and business management of Bracco's highly successful Empower contrast injector lines, novel angiographic injection technologies, patient monitoring systems, CTC & gastroenterology products, medical consumables and Healthcare IT lines from their inception.



• Drew Taylor, Lead Medical Researcher, Epic Capital Management

Dr. Taylor is the Lead Medical Researcher for Epic Capital Management. He is also CEO for Acorn Biolabs, a Toronto based company providing personalized cell cryopreservation and genetics. He has a strong background in basic sciences and clinical medicine with specific attention to tissue engineering and regenerative medicine. Dr. Taylor holds a BS and MSc in Molecular, Cellular, and Developmental Biology from the University of Michigan, and a PhD in Biomedical Engineering from the University of Toronto.

• John Steuart, Managing Director, Steuart Ventures



John has been managing venture capital funds for more than 20 years, at Alafi Capital, Claremont Creek Ventures (co-founder), Prolog Ventures, and Steuart Ventures. John also co-founded CyberGold, an Internet payments and loyalty marketing company. The founding team built the company from three co-founders to 150 employees and took it public. After that came a \$500 million merger with a competitor, Mypoints. The combined company was acquired by United Airlines. John spent the next couple of years working at its corporate VC arm, United Airlines New Ventures. In 2007, John led the Series A investment in Natera together with Sequoia Capital. The molecular diagnostic company successfully completed an IPO in July 2015. John currently invests in testing technologies and digital health. In August 2015 Roche acquired John's portfolió company GeneWeave in a \$425 millión transaction. In August 2016, Myraid Genetics purchased John's portolio company Assurex in a \$410 million deal. John currently serves on the boards of Natera (NTRA), SmartZip, TOMA Bio, and Rally4.



TRACK 3: ENTREPRENEUR WORKSHOPS



Track 3	Presenters
9:00 - 9:50 AM LIFE SCIENCE NATION Connecting Products, Services & Capital FUNDRAISING BOOT CAMP	• Dennis Ford, Founder & CEO, <i>Life Science Nation</i> ; Creator of RESI Conference Series
10:00 - 10:50 AM VENTURE VALUATION SLOBAL VALUATION SERVICES DEAL & PRODUCT VALUATIONS	• Aitana Peire, Business Analyst, Venture Valuation
11:00 - 11:50 AM McDermott Will & Emery NEGOTIATING TERM SHEETS	 Ling Kong, Partner, McDermott Will & Emery, New York Todd Finger, Partner, McDermott Will & Emery, New York Joseph Singh, EVP, Investment Strategy, Excelyrate Management (Mass Innovation Labs) Jim Iversen, CEO, Sen-Jam Pharmaceutical

9:00 - 9:50 AM FUNDRAISING BOOT CAMP - PRESENTER



• **Dennis Ford,** Founder & CEO, *Life Science Nation*; Creator of RESI Conference Series **Workshop:** Fundraising Boot Camp

Dennis Ford is an entrepreneur and author with expertise in sales, marketing, and business development. He has spent most of his career launching new companies. Over the last decade, he has worked extensively with global alternative investors interested in high-growth early-stage technologies. His expertise encompasses using database subscription services to create business solutions and using the Internet to create an interactive dialog between buyers and sellers. He is a big proponent of using profiling and matching technology to find that all-important business fit in the marketing and selling process. Before LSN, Dennis was the President and CEO of Brighton House Associates (BHA). BHA was launched in order to improve the way hedge fund and private equity fund managers raised capital and marketed their funds to investors. Ford is the author of *The Peddler's Prerogative* and *The Life Science Executive's Fundraising Manifesto*, two well-received sales and marketing books.

TRACK 3: ENTREPRENEUR WORKSHOPS

PRESENTERS

McDermott
Will&Emery



• Aitana Peire, Business Analyst, Venture Valuation Workshop: Deal and Product Valuations

Before joining Venture Valuation in 2013 as business analyst, Aitana worked as Pharma equity research analyst for Kepler Cheuvreux, covering small caps. Prior to that, she worked as consultant for Stratas Partners, based in Basel, focusing on projects on market access, pricing and reimbursement, and budget impact modelling. Aitana holds a PhD in Evolutionary Genetics from the University of Groningen (Netherlands) and is a CFA Level II candidate.



• Ling Kong, Partner, McDermott Will & Emery, New York

Workshop: Negotiating Term Sheets: What's Best for the Company and What's Best for You?

Ling W. Kong represents clients in a range of corporate transactions and financings, including mergers, stock and asset purchases and sales, venture capital investments, joint ventures, restructurings and recapitalizations. Ling has represented companies and investors in a wide range of sectors, including alcohol beverage, chemicals, energy, manufacturing, medical devices, packaging, pharmaceuticals, software, sporting equipment and technology. Ling was a summer associate in the Firm's New York office. Prior to joining McDermott, he was a summer associate at a US media law firm. While in law school, he served as the president of the law school student body and the Asian Pacific American Law Students Association and was a note editor of the American Journal of Law and Medicine.



• Todd Finger, Partner, McDermott Will & Emery, New York
Workshop: Negotiating Term Sheets: What's Best for the Company and What's Best for You?

Todd Finger represents clients in the full range of corporate transactions and financings, including mergers, stock and asset purchases and sales, leveraged buyout transactions, venture capital investments, joint ventures, restructurings and recapitalizations. Todd has deep experience in the entertainment and media industries. He also advises clients with interests and operations in the life sciences, consumer products, food and beverages, and fashion and apparel industries, among other sectors. Todd is the head of the New York office's Transactions Practice Group. In addition to his corporate and operating company clients, Todd negotiates financings and transactions on behalf of private equity and venture capital firms with respect to their investments in public and private companies. Earlier in his career, Todd worked at the White House under US President William J. Clinton, and on the presidential campaign of Vice President Al Gore.



• Joseph Singh, EVP, Investment Strategy, Excelyrate Management (Mass Innovation Labs)
Workshop: Negotiating Term Sheets: What's Best for the Company and What's Best for You?

Joe is a seasoned private equity investment and operating executive with a strong track record of creating value and driving revenues for shareholders and corporate sponsors in the Financial Services, Life Sciences and Technology industries. Joe's leadership roles include Executive tenures at Bankers Trust, JP Morgan and PwC/IBM. Most recently, he served as an Entrepreneur in Residence at MIT's Sloan School of Business. Joe is an advisor to Rosc Global Investments, Mark Fuller's Family Office, and is an EVP at Excelyrate Management, the Investment and Venture arm of Mass Innovation Labs'. In the past, he has served as Treasurer on the Board of Governors, and on the House Committee of the Columbia University and Princeton University Clubs, respectively.



• Jim Iversen, CEO, Sen-Jam Pharmaceutical
Workshop: Negotiating Term Sheets: What's Best for the Company and What's Best for You?

Jim Iversen is a growth-focused Senior Executive and Board Member with more than 30 years of success spanning energy, transportation, distribution, enterprise, software, warehouse management, life science, consumer products, and engineering. Leveraging extensive experience in strategic, resourceful leadership, Jim is a valuable asset for small to mid-sized companies requiring expert assistance with business growth and development, evaluating and positioning selling, turnaround management, and strategic planning. His broad areas of expertise include business strategy, leadership training and development, company culture, and business growth. Throughout his executive career, Jim has held leadership positions with JMI Capital Group, Northern Reliability, M&I Strategic Partners, W&H Systems, Horizon Foods, and AL Systems. He is currently the CEO of JMI Capital Group, which provides companies with business strategy and M&A advisory services. In this role, Jim has been responsible for advising a leading Enterprise Resource Planning software company, resulting in a successful sale and a 25% IRR, and a leading supply chain company, resulting in a successful sale and 36% IRR. In a previous role as CEO of M&I Strategic Partners, which provides businesses with software solutions, Jim led the acquisition of AL Systems and Mincron Software Solutions, resulting in a significant increase in each company's revenue and EBITDA growth.



TRACK 4: **ASIA - NORTH AMERICA WORKSHOP & PANELS**





Track 4 **Presenters, Moderators & Panelists** 1:00 - 1:50 PM **ASIA INVESTORS** LANDSCAPE

China Leads Charge to North America

• Lucy Parkinson, Director of Investor Research, Life Science Nation

• James Huang, Research Analyst, Life Science Nation

2:00 - 2:50 PM

ASIA MEDTECH INVESTORS

Understanding the Asian Medtech Market: Key Differences & **Current Opportunities**

• Mark Tang, Managing Director, Good Health Capital (M)



- Akihiro Maeda, Manager of Business Development, Teijin Pharma
- Jean Yao, Managing Partner, Med Qiao Group
- Kathy He, Venture Partner, Advantech Capital
- Zheng Song, Managing Director, Decker Capital

3:00 - 3:50 PM

ASIA THERAPEUTICS INVESTORS

Exploring Asian Therapeutic Industry: What's Different? What's Big?

• Richard Soll, Senior VP, Research Service Division (RSD), WuXi AppTec (M)



- George Syrmalis, CEO, The IQ Group
- Michael Baran, Sr. Director, Worldwide R&D, Strategic Portfolio Management, Pfizer
- Mohamad Tabrizi, SVP, Business Development, ShangPharma Innovation
- Weiyong Sun, Sr. Director External Scientific Affairs, Daiichi Sankyo Group



WORKSHOP: ASIA INVESTORS LANDSCAPE - PRESENTERS 1:00 - 1:50 PM



• Lucy Parkinson, Director of Investor Research, Life Science Nation

Lucy Parkinson is LSN's Director of Investor Research, and leads LSN's investor outreach and analysis team. She additionally contributes to LSN's web marketing as the voice of LSN's videos and a contributing writer on both The Life Science Executive's Fundraising Manifesto and the Next Phase newsletter. Prior to joining LSN, Lucy spent several years working at CPA firms, gaining experience working with small corporations, partnerships and nonprofit organizations. Lucy graduated from the University of Leeds with a degree in the History and Philosophy of Science. She is also a FINRA-registered securities principal and an Enrolled Agent.





James Huang is a Research Analyst for LSN in Boston, Massachusetts. Previously, James served as a Research Assistant in the Hematology Division at Washington University in St. Louis, growing modified TFPI and developing assays to detect the efficiency of these mutations. Previously, he served as an analyst at Informulary, a start-up dedicated to analyzing FDA clinical trial data and systematic review data to extract relevant data for use in more easily understood drug labels and for use in advising self-insured employers determine medications to be covered in their formularies. Currently, as a Research Analyst at Life Science Nation (LSN), he collaborates with investors in various life science sectors such as therapeutics, medical devices, diagnostics, and healthcare IT. James also works closely with many Chinese investors and has written articles on the Chinese market based on conversations with these investors and research he has done on the topic. James received his B.A. in Neuroscience from Dartmouth College.

2:00 - 2:50 PM ASIA MEDTECH INVESTORS

TRACK 4 PANELISTS

SPONSORED BY





• Mark Tang, Managing Director, Good Health Capital (M)

Mark Tang is a managing director of Good Health Capital, a healthcare private equity firm with offices in Asia and New York. Mark has over two decades of experience in the field of biotechnology as an entrepreneur, educator, advisor and investor. He was formerly a research associate at Rockefeller University and a biotech director at Rutgers Business School. Mark holds several degrees including an MPH from Harvard.



• Akihiro Maeda, Manager of Business Development, Teijin Pharma

Akihiro (Aki) Maeda joined Teijin Pharma Ltd in 2002, Tokyo-basis Company with unique business specialties managing both pharmaceutical and medical devices. As a business development manager heading strategic alliance in medical device section of the company especially for home healthcare, with North American potential partners, Aki dedicates to support bridging all aspects of collaboration such as technology license, joint research/development, clinical study in Japan, regulatory process, reimbursement strategy and product distribution, between Teijin and early stage companies, working at Bay Area in California as a North America representative in the company. Prior to career of business development in the company, Aki managed internal product development projects in the field of pulmonary and stroke rehabilitation, involving foreign and Japanese domestic companies implementing his own patents to the products. Aki received a Master of Engineering (M.Eng.) from Meiji University Graduate School in Japan and a Bachelor of Engineering from Meiji University.



• Jean Yao, Managing Partner, Med Qiao Group

Jean Yao, PhD, is the founder of Med Qiao Group and has been active within the technology community for over twenty years as a venture capitalist, consultant and technologist. She brings broad experience in the Bio/Med-Industry, having worked with startups, institutional and strategic VCs to expand the market in China. With strong technical background in bio-med development, she has high interest in emerging technologies, including Diagnostics, Medical technology and Health IT.



• Kathy He, Venture Partner, Advantech Capital

Kathy He is the Venture Partner of Advantech Capital where she sources and executes cross-border private equity investments in healthcare. Kathy assists portfolio companies with growth strategies and cross-border M&A, and is the Board Director for Diagnostic Photonics, an intraoperative medical imaging company. Previously, Kathy was the North America Managing Director for Fosun Pharma, VP of Corporate Strategy and Business Development of Prosorp Biotech Inc, Commercial leader for Takeda Pharmaceuticals, and Senior Manager for Merck and Abbott Diagnostics. Kathy was Founder and CEO of VIVREGEN, a biotech company that successfully developed and commercialized a regenerative therapy to improve animal health. Kathy earned her B.S. in Biology at Wuhan University, MS in Cell and Structural Biology at University of Illinois at Urbana-Champaign, and MBA at Northwestern University – Kellogg School of Management.



• Zheng Song, Managing Director, Decker Capital

Ms. Song is a founding member of Decker Capital. She has over 20 years of investment banking and asset management experience. Ms. Song is a native of Beijing who has studied and worked in the U.S. since 1990. She went to Beijing as a founder and Managing Director of MDC China Fund I in 2008 and returned to the U.S. in 2014 after successfully liquidating her first fund, MDC China Fund I, which was focused on private equity investing in the People's Republic of China. In 2009, Ms. Song and MDC's team successfully established MDC China Fund I, a private equity fund focused on investing in retail, consumer and media industry operating in the People's Republic of China. The Fund successfully completed a USD \$41.5 million investment into Beijing New Cooperation Supermarket Chain Co. (NCSN) in 2010 and exited the investment in 2014. Ms. Song is responsible for identifying investment opportunities and managing relationships with Chinese clients and investors. She is an active member and Director of the China Entrepreneur Committee which consists of 270 leading Chinese enterprises in China. Ms. Song is a frequent speaker at various investment, financing and economic forums and association conferences. Before founding Decker Capital in 2007, Ms. Song had 9 years of investment banking experience during her tenure in the Corporate Finance and M&A Group at Credit Lyonnais Securities in New York and UBS Warburg in Hong Kong where she completed a number of M&A, Initial Public Offering, Private Placement, Equity and ADR transactions. Ms. Song started her career as a member of General Electric Company Information Management Leadership Program.

3:00 - 3:50 PM **ASIA THERAPEUTICS INVESTORS**

TRACK 4 PANELISTS

SPONSORED BY





• Richard Soll, Senior VP, Research Service Division (RSD), WuXi AppTec (M)



Dr. Richard Soll is Senior Vice President, Research Service Division (RSD), at WuXi AppTec and leads the WuXi offices in Cambridge, Massachusetts and in Israel to bring WuXi's comprehensive platform of integrated R&D services closer to innovative companies and entrepreneurs in the world's two leading biotech hubs. Dr. Soll's contributions to drug discovery and development led to the discovery of the HCV breakthrough therapy elbasvir, the JAK2 inhibitor fedratinib, and more than 10 other clinical stage drugs. Dr. Soll has co-authored more than 100 patents and papers. Dr. Soll serves on the board of the Accelerator has been an SAB member to biotech companies and advisor to entrepreneurs. Prior to WuXi, Dr. Soll was CSO and VP of R&D at TargeGen where he led multiple clinical stage R&D programs. Dr. Soll founded the chemistry department at 3-Dimensional Pharmaceuticals as VP of Chemistry. Dr. Soll began his industry career at Wyeth Pharmaceuticals, and was trained as a synthetic chemist at Dartmouth and Harvard.



• George Syrmalis, CEO, The IQ Group

Dr George Syrmalis is the founder and Group Chief Executive Officer of The iQ Group Global, he is trained in Nuclear Medicine and also has a PhD in Radiation Immunology. Dr Syrmalis is regarded as an innovative biotechnology strategist and successful life science entrepreneur. He is regularly sought for his views on investing in the biotechnology sector. His interests lie in the area of translational medicine and biomarkers. The iQ Group Global provides a turnkey solution for life sciences companies, spanning corporate advisory and investment banking, through to research, development, commercialization and sales. The Group facilitates an end to end solution along the drug lifecycle creating the medicines of tomorrow.



• Michael Baran, Sr. Director, Worldwide R&D, Strategic Portfolio Management, Pfizer

Mike is responsible for critically assessing the Pfizer R&D portfolio from a volume, value, quality, risk and productivity perspective with the ultimate objective of maximizing R&D productivity and value generation. He also provides strategic support to the External Science & Innovation (ES&I) group, working to identify academic, biotech, pharmaceutical and government partners. From 2011-2017 Mike was Senior Director, Scientific Affairs for the R&D President's Office where he was responsible for enabling and communicating the R&D strategic agenda as well as leading colleague development capabilities. Mike joined Pfizer in 2008 in the market access space providing strategic and analytical support around marketing and managed care contracting with commercial and government payers. Prior to 2008, Mike worked within the NIH Protein Structure Initiative's Northeast Structural Genomics Consortium coordinating protein structure production efforts, including bioinformatics, protein expression/purification and 3D structure determination. Mike is also a co-founder of Nexomics Biosciences, a NJ based biotechnology company focused on providing gene-2-structure services as well as early stage drug target validation. He is actively involved in the local biotechnology community participating in eLabNYC, an organization which aims to connect entrepreneurs from New York City academic institutions with local scientific and business leaders.



• Mohamad Tabrizi, SVP, Business Development, ShangPharma Innovation

Mohamad M. Tabrizi is Senior Vice President at ShangPharma Innovation. He has over 25 years of experience in the life sciences industry as an investor, entrepreneur, business development professional, investment banker and scientist. Previously Mr. Tabrizi spent 10 years leading business development efforts at Nektar Therapeutics. He was head of west coast healthcare investment banking for Needham and Sr. banker with RBC Capital markets and Merrill Lynch. As a sceintis Mr. Tabrizi worked at Howard Hughes Medical Institute and Stanford University School of Medicine. Mr. Tabrizi received and MBA from Cornell University and a Masters of Science from Stanford University.



• Weiyong Sun, Sr. Director External Scientific Affairs, Daiichi Sankyo Group

Dr. Weiyong Sun is currently Senior Director, External Scientific Affairs, Global Business Development and Licensing at Daiichi Sankyo Group. He joined Daiichi Sankyo Japan in April 2002. He was involved in a broad range of R&D activities from target discovery to clinical development of a number of anti-diabetes drugs. In October 2007, Dr. Sun was elected to be assigned to work for Daiichi Sankyo Research Institute in the U.S. He was responsible for identifying and evaluating in-licensing, partnering and research collaboration opportunities. His current focus is in Thrombosis & Thrombolysis, Pain, Cardio-Renal, Ophthalmology and Rare Disease. Dr. Sun received an M.D. from Beijing Medical University (now Peking University Medical School), a Ph.D. in Biochemistry from the University of Tokyo and an MBA from Columbia Business School. He was a postdoctoral fellow in the Blood Research Institute, Medical College of Wisconsin.

Life Science Nation accelerates fundraising with its matching platform to create relationships between early stage scientist-entrepreneurs and emerging life science investors.







INVESTOR PLATFORM

5,000 early stage life science investors across **10** categories



COMPANY PLATFORM

45,000 emerging biotech, medtech, diagnostic and healthcare IT companies

CONSULTING SERVICES

- Branding & Messaging
- Fundraising Workshops
- Sourcing & Ranking Service
 - Vetting & Ranking
 - Expert System
 - Secure Data Vault





FUNDRAISING ADVISORY FIRM

Providing tactical assistance in executing fundraising campaigns in the biotech and medtech arenas

GLOBAL NETWORK OF INVESTORS

Securing meetings and fostering relationships with qualified investors that are a fit

INTEGRATED WITH LSN & RESI

Making your fundraising more efficient and effective based on technology and relationships



PARTNERING FORUM

SPONSORED BY

TRACK 5

Johnson Johnson Innovation

– JLABS –

STRENGTH IN NUMBERS






1,000+ Meeting Slots

82% C-Level Executives

Who Meets with Whom at RESI Conferences



Investor Type	Percentage
Large Pharma/Medtech	23%
Venture Capital	20%
Family Office/Private Wealth	14%
Corporate Venture Capital	13%
Angel	10%
Government Organization	9%
Endowments/Foundations	3%
Private Equity	3%
Institutional Alternative Investor	3%
Hedge Fund	2%

RESI provides a partnering forum for all stakeholders in the early stage life science world to reach out to others and build the relationships that will carry new technologies towards commercialization.







Title Sponsors









Gold Sponsor



Bronze Sponsors







SPONSORS



Johnson Johnson innovation

– JLABS –

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow – all in a no-strings-attached model. The JLABS network includes eight facilities, located in San Diego the Bay Area, Boston & Lowell, MA, Houston, Toronto including a new location, New York City, launching in 2018.



Life Science Nation (LSN) accelerates fundraising using its matching platform to create highly compatible relationships between early stage scientists/ entrepreneurs and emerging technology investors. LSN researches and curates market intelligence on two industry sectors: The first is emerging biotech and medtech companies, which by their ephemeral nature are challenging to find and track. Second, LSN tracks ten categories of early stage life science investors and identifies who is filling the void left by venture capital. LSN owns and operates the Redefining Early Stage Investments (RESI) conference series, which brings together global early stage biotech and medtech companies with early stage investors.



WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit http://www.wuxiapptec.com



McDermott Will & Emery is a premier international law firm with a diversified business practice. Established in 1934 as a tax practice in Chicago, Illinois, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. McDermott has 80 years of serving a broad range of client interests. Our Life Sciences Industry Group is composed of 135 professionals, 60 with advanced science degrees and many others with government and industry experience, working across 19 offices around the world. With insights drawn from the only health practice ranked Tier 1 nationally by Chambers USA and our global reach, we deliver integrated business solutions to our clients, bringing the required experience from our leading tax, health, intellectual property, antitrust and regulatory practices to solve our client's challenges.



Merck has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide... and many of these advances were the result of partnerships. In 2016, more than 60% of our human health sales were attributable to alliance partnerships and patents and we continue to work with our partners in some of the most challenging areas of biomedical research. With more than 100 business development transactions since 2015, our team has experience working on collaborations from discovery to clinical-stage programs regardless of therapeutic area or modality. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life. Learn more at merck.com/licensing.



Created in 1979 by the healthcare technology industry, Medmarc's purpose is to be the superior provider of liability insurance and related risk management solutions and to support the development, testing and delivery of medical products that save lives and improve the quality of life. Through collaboration with our parent company, ProAssurance, and our clinical trial industry experts, we provide a single source of innovative healthcare liability insurance solutions to the life sciences companies we serve. From ideas and prototypes to the reality of commercialization and success – We can Meet Your Changing Needs. Call me to discuss the cost of insurance coverage, what coverages are needed and when for your business plan. George Ayd (703)652-1309



At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

MEDIA PARTNERS





Media Partners



































SUPERIOR PROTECTION

FOR MEDICAL TECHNOLOGY AND LIFE SCIENCES COMPANIES

For more information or to subscribe to our newsletter visit Medmarc.com/News or email us medtechlifesci@medmarc.com

WHAT NUMBERS ARE NEEDED FOR A BUSINESS PLAN?

- Insurance coverages and cost typically needed to start a business
- Clinical trial insurance pricing and requirements in and outside of the United States

Find out, call George Ayd at 703-652-1309 or email gayd@medmarc.com

We are an alliance of insurance specialists, each with a deep understanding of the medical technology and life sciences environments, each well versed in the specific challenges you face. Our combined expertise is unmatched in the industry and translates into comprehensive coverage and risk management solutions which help you protect your balance sheet and control insurance costs.



800.788.0194 | Medmarc.com



Strategic **PARTNERSHIP** is at the heart of fulfilling Pfizer's purpose as we work to translate advanced science and technologies into medicines and vaccines that significantly improve patients' lives.



www.pfizer.com/partners/research-and-development

Visit the Pfizer partnering website to learn more about:

- Our Areas of Interest
- Our Process
- Partnering Highlights
- Our Partnering Leadership
- Contact Information





CONFERENCE SERIES



SAN FRANCISCO, CA JANUARY 9, 2018







SAVE THE DATES



TORONTO, ON APRIL 10, 2018



